

GEORGE E. PEOPLES, JR., M.D., F.A.C.S.
Colonel (retired), Medical Corps
United States Army

**FOUNDER AND DIRECTOR
CANCER VACCINE DEVELOPMENT PROGRAM**

PROFESSOR OF SURGERY
UNIFORMED SERVICES UNIVERSITY
OF THE HEALTH SCIENCES
BETHESDA, MD

HOME

300 East Base Road, #1112
San Antonio, TX 78209
Phone: (210) 557-4291
E-mail: georgepeoples2@hotmail.com

**FOUNDER AND CEO
CANCER INSIGHT, LLC**

PROFESSOR (ADJUNCT)
DEPARTMENT OF SURGICAL ONCOLOGY
M.D. ANDERSON CANCER CENTER
HOUSTON, TX

WORK

110 East Houston Street, Floor 7
San Antonio, TX 78205
Phone: (210) 557-4291
Email: gpeoples@cancerinsight.com

EDUCATION

- | | | | |
|------|---|----------------|------|
| ▪ MD | Johns Hopkins University School of Medicine | Baltimore, MD | 1988 |
| ▪ BS | United States Military Academy | West Point, NY | 1984 |

SURGICAL TRAINING

Fellow	M.D. Anderson Cancer Center Surgical Oncology	1996-1998
Resident	Harvard Medical School Brigham and Women's Hospital General Surgery	1994-1996
Research Fellow	Harvard Medical School Brigham and Women's Hospital Department of Surgery	1991-1994
Resident	Harvard Medical School Brigham and Women's Hospital General Surgery	1989-1991
Intern	Walter Reed Army Medical Center General Surgery	1988-1989

AWARDS AND HONORS

MILITARY AWARDS

- Legion of Merit 2014
 - Order of Military Medical Merit 2006
 - "A" Designator 2006
 - Bronze Star 2002, 2003
 - Combat Medical Badge 2002, 2003
 - Army Commendation Medal with Valor Device 2003
 - Presidential Unit Citation 2003
 - Joint Meritorious Unit Award 1998, 2002
 - Meritorious Service Medal 2001, 2010
 - Army Commendation Medal 1998, 2001, 2003, 2009
 - Joint Services Achievement Medal 1998, 2005
 - Army Achievement Medal 1999, 2012
 - Navy Achievement Medal 2009
 - Army Expeditionary Medal 2003
 - Afghanistan Campaign Medal 2005, 2009
 - Iraq Campaign Medal 2005, 2010
 - Humanitarian Service Medal 1998
 - GWOT Service Medal 2002
 - GWOT Expeditionary Medal 2002, 2003
 - NATO Medal 2009
 - SSI/WTS 2002, 2003, 2009, 2010
- 3rd SFG, 5th SFG, 528th FSB (USASOC), 44th Med Bde, 3rd ID, 101st A/ASID, 82nd AID, 30th Med Bde, 1st Med Bde

JUNIOR CHAMBER OF COMMERCE

- Ten Outstanding Young People of the World Award 2001
- Ten Outstanding Young Americans Award 2001

BROOKE ARMY MEDICAL CENTER

- Gold Headed Cane Award 2010

WALTER REED ARMY MEDICAL CENTER

- TRICARE Hero 2001
- Customer Service Excellence Award 2000
- Letterman Award – Officer Advance Course 1999

UNIVERSITY OF TEXAS – M.D. ANDERSON CANCER CENTER

- Clinical Trainee Recognition Award Finalist 1998
- American Association for Cancer Research Scholarship
Methods in Clinical Research, Vail, CO 1997
- Fellow's Research Award 1997

HARVARD MEDICAL SCHOOL – BRIGHAM AND WOMEN'S HOSPITAL

- American Cancer Society Clinical Oncology Fellowship 1995-1996
- Harvard Medical School Excellence in Teaching Award 1995-1996

- Massachusetts Chapter of the American College of Surgeons
Resident Prize Essay Competition Winner 1993, 1994

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

- Alpha Omega Alpha 1988
- Phi Beta Kappa 1988
- CIBA Award for Community Service 1986

UNITED STATES MILITARY ACADEMY

- Association of Graduates Award for Academic Excellence 1984
- Salutatorian 1984
- Phi Kappa Phi 1983-1984

ADMINISTRATIVE RESPONSIBILITIES

CEO	Cancer Insight, LLC	2014-present
Director	Cancer Vaccine Development Program	2002-present
Associate Editor	<i>Clinical Cancer Research</i>	1998-present
Chief	Surgical Oncology Brooke Army Medical Center	2006-2014
Chairman	Cancer Care Committee Brooke Army Medical Center	2006-2014
Director	Breast Cancer Care Clinic Brooke Army Medical Center	2006-2014
Deputy Director	United States Military Cancer Institute	2007-2011
Associate Director for Clinical Trials	United States Military Cancer Institute	2005-2011
Membership Committee	Society of Surgical Oncology	2005-2008
Member	Joint Readiness Clinical Advisory Board Fort Detrick, MD	2004-2006
Member	Scientific Review Committee United States Military Cancer Institute	2004-2006
Member	Risk Management Committee Brooke Army Medical Center	2006-2009

Chief	Surgical Oncology Walter Reed Army Medical Center	2001-2006
Head	Tumor Board Walter Reed Army Medical Center	2001-2006
Surgical Coordinator	CALGB Walter Reed Army Medical Center	2004-2006
Member	Cancer Care Committee Walter Reed Army Medical Center	2004-2006
Member	Human Use Committee Department of Clinical Investigation Walter Reed Army Medical Center	2000-2006
Moderator	Cancer Forum Society of Surgical Oncology	2004, 2006
Member	Program Committee Gary P. Wratten Surgical Symposium	2004, 2006
Moderator	Basic Science Session Gary P. Wratten Surgical Symposium	2004, 2006
Member	Board of Directors Endowment Fund for the National Capitol Area Breast Care Center	2000-2001
Member	Forum Committee and Case Review Committee All Surgeon's Day Metropolitan Washington Chapter of the American College of Surgeons Washington Academy of Surgeons	2000-2001
Coordinator	General Surgery Service Quality Improvement	2000-2001

ACADEMIC/PROFESSIONAL APPOINTMENTS

Professor (adjunct)	Department of Surgical Oncology Division of Surgery U.T. MD Anderson Cancer Center	2009-present
Professor of Surgery	Uniformed Services University of the Health Sciences	2008-present
Assoc Professor of Surgery	Uniformed Services University	2002-2008

	of the Health Sciences	
Chief, Surgical Oncology	Brooke Army Medical Center	2006-2014
Chief, Surgical Oncology	Walter Reed Army Medical Center	2001-2006
Surgical Oncologist	Walter Reed Army Medical Center	1998-2001
Asst Professor of Surgery	Uniformed Services University of the Health Sciences	1997-2001
Adj Asst Professor of Surgery	U.T. MD Anderson Cancer Center	1998-2001
Junior Faculty Assoc	U.T. MD Anderson Cancer Center	1996-1998
Surgical Oncology Fellow	U.T. MD Anderson Cancer Center	1996-1998
Clinical Oncology Fellow	American Cancer Society	1995-1996
Clinical Fellow in Surgery	Harvard Medical School	1989-1996
Research Fellow	Laboratory of Biologic Cancer Therapy Harvard Medical School and Brigham and Women's Hospital	1991-1994
Surgical Resident	Brigham and Women's Hospital	1989-1996
Surgical Intern	Walter Reed Army Medical Center	1988-1989

MILITARY TRAINING/SERVICE

Chief Surgeon	Joint Task Force – Bravo Soto Cano, Honduras	2012
Deputy Commander, Clinical Services	21 st Combat Support Hospital Tikrit, Iraq	2010-2011
Chief Surgeon	126 th Forward Surgical Team Afghanistan	2008-2009
Chief Surgeon	Joint Task Force – Bravo Soto Cano, Honduras	2005
Graduate	US Army Command and General Staff College	2004
Chief Surgeon	274 th Forward Surgical Team Operation Iraqi Freedom	2003

	Kuwait – Iraq	
Senior Surgeon	274 th Forward Surgical Team Operation Enduring Freedom Uzbekistan – Afghanistan	2001-2002
Deputy Commander for Clinical Services	28 th Combat Support Hospital Hospital Unit Forward Fort Bragg, NC	1999-2001
Surgeon (backfill)	Heidelberg Army Community Hospital Heidelberg, Germany	2000
Surgeon, 28th CSH	Joint Readiness Training Center Fort Polk, LA	1999
AMEDD Officer Advance Course	Fort Sam Houston, TX	1999
Medical Management of Chemical Biologic Course	Fort Sam Houston, TX	1999
Chief Surgeon	Joint Task Force – Bravo Soto Cano, Honduras	1998
Combat Casualty Course	Fort Sam Houston, TX	1988
Air Assault School	Fort Campbell, KY – Honor Graduate	1985
AMEDD Officer Basic Course	Fort Campbell, KY	1985
United States Military Academy	West Point, NY	1984
Airborne School	Fort Benning, GA	1982

CLINICAL TEACHING EXPERIENCE

General Surgery Core Clerkship	Uniformed Services University of the Health Sciences	1998-
General Surgery Core Clerkship	University of Texas School of Medicine	1996-1998
General Surgery Core Clerkship	Harvard Medical School	1989-1996

INVITED LECTURER

1. Cancer Immunology, **Center for Prostate Disease Research**, Washington, DC, 3/98

2. Basic Science Review: Molecular and Cellular Biology, ACS Review Course, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 1/00
3. Basic Science Review: Immunology, ACS Review Course, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 1/00
4. Peptide-Based Cancer Vaccines, **Zonagen**, The Woodlands, TX, 3/00
5. Cancer Immunology: Vaccine Development, Visiting Professor Lectureship, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 5/00
6. Any Good News About Cancer? **PWCC Heritage Ball**, Washington, DC, 10/00
7. Cancer Vaccine Development, **Baxter Healthcare**, Columbia, MD, 11/00
8. Peptide-Based Cancer Vaccine Design, Tri-Service Grand Rounds, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 11/00
9. Basic Science Review: Molecular and Cellular Biology, ACS Review Course, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 1/01
10. Basic Science Review: Immunology, ACS Review Course, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 1/01
11. Cancer Prevention, **Capitol Exchange Club**, Washington, DC, 6/01
12. HER2/neu Vaccine Trials: US Military Cancer Institute (USMCI) Basic Science Seminar Series, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 6/01
13. Prostate Vaccines: An Update, **Center for Prostate Disease Research – Laboratory Meeting**, Rockville, MD, 7/01
14. Update on Cancer Vaccine Trials, **United States Military Cancer Institute**, Washington, DC 6/02
15. The 274th FST Experience During Operation Enduring Freedom: Visiting Professor Lectureship, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 9/02
16. The 274th FST Experience During Operation Enduring Freedom: 17th Annual Surgery for Trauma Symposium, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 9/02
17. Combat Casualties Cared for by the 274th FST and Blood Use During Operation Enduring Freedom, **Walter Reed Army Institute of Research**, Forrest Glenn, MD, 10/02
18. USMCI Cancer Vaccine Program Board of Scientific Directors, **Walter Reed Army Medical Center**, Washington, DC, 11/02
19. Basic Science Review: Immunology, ACS Review Course, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 1/03

20. The 274th FST Experience During Operation Iraqi Freedom: Visiting Professor Lectureship, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 9/03
21. Overview of the Prostate Vaccine Program, Oversight Committee, **Center for Prostate Disease Research**, Rockville, MD, 10/03
22. Operation Iraqi Freedom, **Rotary Club**, Columbia, MD, 12/03
23. Cancer Vaccine Trials, All Surgeon's Day, **American College of Surgeons, Washington Chapter**, Washington, DC, 2/04
24. Preventive HER2/neu Vaccine Trials, **Society of Surgical Oncology Tumor Immunology Symposium**, New York, NY, 3/04
25. 274th Forward Surgical Team in Operation Iraqi Freedom, **American Medical Association National Advocacy Conference**, Washington, DC, 3/04
26. Lessons Learned from OIF at the FST Level, **Lessons Learned from Deployments Symposium, Walter Reed Army Medical Center**, Washington, DC, 4/04
27. Lessons Learned from OIF at the FST Level, **US/UK Far Forward Surgery Conference**, London, England, 8/04
28. HER2/*neu* Vaccines in Cancer, **Gynecology/Oncology Grand Rounds, Walter Reed Army Medical Center**, Washington, DC, 11/04
29. War Surgery 2005: New Concepts and Technologies, **Surgery Grand Rounds, Department of Surgery, Johns Hopkins University School of Medicine**, Baltimore, MD, 2/05
30. Testing HER2/*neu* Peptides in Preventive Clinical Trials, **Human Immunology Symposium, Johns Hopkins University School of Medicine**, Baltimore, MD, 3/05
31. Advances in Combat Casualty Care, **Urban Warfare Conference**, Washington, DC, 4/05
32. Advances in Anesthesia and Surgical Care for Combat Casualties, **Anesthesia Grand Rounds, Department of Anesthesia, Johns Hopkins University School of Medicine**, Baltimore, MD, 8/05
33. HER2/*neu* Vaccines in Cancer, **Combined Surgery and Medicine Grand Rounds, Brooke Army Medical Center**, San Antonio, TX, 8/05
34. Combat Casualty Care in OIF, **Mid-Atlantic Association of Blood Banks**, Annapolis, MD, 3/06
35. Vaccine Clinical Trials for Breast Cancer, **Oncology Update 2006 Conference, University of Pittsburgh at Johnstown**, Johnstown, PA, 4/06
36. Development and Testing of Clinical Cancer Vaccines, **Uniformed Services University of the Health Sciences**, Bethesda, MD, 9/06

37. Breast Cancer Vaccine Clinical Trials, **American College of Physicians, Army Chapter**, Alexandria, VA, 11/06
38. Combined Results of a HER2/*neu* Vaccine for the Prevention of Recurrence in High Risk Breast Cancer Patients, **Immunology Seminars, M.D. Anderson Cancer Center**, Houston, TX, 1/07
39. Breast Cancer Vaccines: Future Promise, **Community Forum, Trinity Mother Frances Hospital, Conference Center**, Tyler, TX, 2/07
40. Breast Cancer Vaccines: Future Promise, **10th Annual Tyler Breast Cancer Conference, Harvey Convention Center**, Tyler, TX, 2/07
41. Combined Results of a HER2/*neu* Vaccine for the Prevention of Recurrence in High Risk Breast Cancer Patients, **Medical Oncology Combined Grand Rounds, Brooke Army Medical Center**, Ft. Sam Houston, TX, 2/07
42. Establishing a Research Program as a Clinician, **San Antonio Uniformed Services Health Education Consortium**, San Antonio, TX, 8/07
43. HER2/*neu* Vaccines for the Prevention of Breast Cancer Recurrence, **National Institutes of Health, National Cancer Institute**, Bethesda, MD, 9/07
44. HER2/*neu*-Based Vaccines for the Prevention of Breast Cancer Recurrence, **Eastern Virginia Medical School**, Norfolk, VA, 9/07
45. HER2/*neu* Vaccines for Cancer, **European Society for Medical Oncology International Symposium on Immunology**, Athens, Greece, 11/07
46. HER2/*neu* Vaccines for Cancer Recurrence, **1st Annual USU/HJF Symposium**, Bethesda, MD, 6/08
47. Cancer Vaccines, **36th Annual Texas Tumor Registrars Association Conference**, San Antonio, TX, 9/08
48. Cancer Vaccines, **Eisenhower Army Medical Center Grand Rounds**, Augusta, GA, 9/08
49. Hope for the Future, **Breast Cancer Awareness Luncheon**, San Antonio, TX, 10/08
50. Preventive HER2/*neu* Vaccines for Breast Cancers, **Recent Advances in Cancer Immunotherapy**, Athens, Greece, 10/08
51. HER2 Vaccination in High-Risk Breast Cancer, **Chemotherapy Foundation Symposium XXVI**, New York, NY, 11/08
52. USMCI Clinical Trials Update, **Joint Task Force-Medical Meeting**, Washington, DC, 8/09
53. The Cutting Edge: What's New in Surgical Oncology, **Multi-Disciplinary Breast Cancer Update Symposium**, Brooke Army Medical Center, San Antonio, TX, 9/09

54. Novel Breast Cancer Vaccine Trials, **The South Texas Accelerated Research Therapeutics Center**, San Antonio, TX 2/10
55. Military and Civilian Collaborative Cancer Vaccine Trials in San Antonio, **The Trustees for the Voelcker Fund**, San Antonio, TX 2/10
56. Targeting the Adjuvant Setting in Patients with an Unmet Need: Successful Cancer Vaccine Development, **Cancer Vaccine Meeting**, Cambridge, MA 6/10
57. Update on E75 Phase II trial: 36 mo DFS landmark analysis, **Galena Showcase**, Chicago, IL 6/11.
58. Recent Progress with Peptide Approaches in Cancer Immunotherapy, **2nd Annual Cancer Immunotherapy Conference: A Long Awaited Reality**, New York City, NY 10/11
59. Breast Cancer Vaccines, **Annual Meeting of the European Society of Cancer Immunology and Immunotherapy**, Siena, Italy 10/11
60. Advances in the Search for a Breast Cancer Vaccine, **12th Annual Breast Cancer Awareness Luncheon**, San Antonio, TX 10/11
61. NeuVax: Phase III trial rationale and design, **Health Canada**, Ottawa, Canada 2/12
62. NeuVax Development, **MD Anderson Grand Rounds**, Houston, TX 8/12
63. The Clinical Development of NeuVax, **13th Annual Breast Cancer Update**, San Antonio, TX 9/12
64. Progress with Peptide-based Cancer Vaccines, **3rd Annual Cancer Immunotherapy Conference**, New York, NY 10/2012
65. Cancer Vaccine Trials, **7th Annual Vaccine Meeting**, Pasteur Institute, Paris, France 1/13
66. Breast Cancer Vaccine Clinical Trials, **National Breast Cancer Coalition, Artemis Project**, Napa Valley, CA 3/13
67. Phase III trial of NeuVax, **Sunnybrook/Odette Cancer Center Grand Rounds**, Toronto, Canada 4/2013
68. Breast Cancer Vaccines, **Northwestern Lurie Cancer Center's Lynn Sage Breast Cancer Symposium**, Chicago, IL 9/2013
69. Breast Cancer Immunotherapy, **Alamo Breast Cancer Foundation's Community Education Day**, San Antonio, TX 10/2013
70. Personalized Cancer Immunotherapy, **Health Practice Commission**, Grand Cayman, 1/2014
71. Melanoma Vaccine Strategy, **Orbis Board of Directors and Shareholders' Meeting**, Greenville, SC 1/2014

72. Progress with Peptide Vaccines, **4th Annual Cancer Immunotherapy/Immuno-oncology Symposium**, New York, NY, 3/2014
73. Melanoma Treatment Registry, **Health Practice Commission**, Grand Cayman, 4/2014
74. NeuVax in Combination with Herceptin, **ASCO Updates**, Chicago, IL, 6/2014
75. Cancer Insight, **CEO Summit**, Lost Pines, TX, 11/2014
76. A Novel Approach to Cancer Vaccine Development, **Healthcare Conference**, Grand Cayman, 11/2014
77. The History of NeuVax, **Galena Annual Meeting**, Las Vegas, NV, 1/2015
78. TLPLDC Open Treatment Registry Update and New Ovarian Cancer Trial, **Health Practices Commission and Health Ministry**, Grand Cayman, 3/2015
79. Cancer Vaccine in the Adjuvant Setting, **5th Annual Cancer Immunotherapy/Immuno-oncology Symposium**, New York, NY, 3/2015
80. Phase IIb Adjuvant Trial to Prevent Melanoma Recurrence, **Investigator's Meeting at SSO**, Houston, TX, 3/2005
81. The Dr Mark Taylor Memorial Basic Science Lecture, **Military Surgical Symposium at SAGES**, Nashville, TN, 4/2015
82. A New Generation of the Autologous Tumor/DC Vaccine and Update of Ongoing Trials, **Health Practices Commission and Health Ministry**, Grand Cayman, 9/2015
83. Next Generation Cancer Vaccine Strategies, **6th Annual Cancer Immunotherapy/Immuno-oncology Symposium**, New York, NY, 3/2016
84. An Ounce of Prevention, **Texas Research and Technology Foundation Luncheon**, San Antonio, TX, 5/2016

PRESENTER OR CO-PRESENTER

1. HLA-A2 Presents Tumor-Associated Antigens in Ovarian Cancer, **Massachusetts Chapter of the American College of Surgeons**, 11/92
2. T Cell Recognition of Ovarian Cancer, **Society of University Surgeons**, 2/93
3. HLA-A2 Presents Tumor-Associated Antigens in Ovarian Cancer, **Society of Surgical Oncology**, 3/93
4. Selective Usage of TCR V β Genes in Ovarian-Specific CTL, **American Association for Cancer Research**, 5/93

5. TCR V β 2 and V β 6 Mediate Anti-Tumor Activity in Ovarian Tumor-Infiltrating Lymphocytes, **American College of Surgeons**, 5/93
6. Specific T Cell Receptor V β Recognition of Two Different Antigen Systems Presented by HLA-A2 in Ovarian Cancer, **Society of Surgical Oncology**, 3/94
7. In Vitro Design and Analysis of a Peptide-Based Vaccine for Epithelial-Derived Tumors, **Massachusetts Chapter of the American College of Surgeons**, 5/94
8. Ovarian and Breast Cancer Express Shared Antigenic Peptides Recognized by Tumor-Specific Cytotoxic T Lymphocytes, **American College of Surgeons**, 10/94
9. Recognition of a HER2/neu-Derived Peptide by Tumor-Specific CTL, **9th International Congress of Immunology**, 5/95
10. Tumor-Infiltrating Lymphocytes Produce Wound-Healing Growth Factors in the Tumor Environment, **Society of Surgical Oncology**, 3/96
11. Tumor-Infiltrating Lymphocytes Produce Potent Vascular Growth Factors in the Tumor Environment, **American Association for Cancer Research**, 4/96
12. Ovarian Cancer-Associated Lymphocytes Recognize Folate Binding Protein (FBP) Peptides, **Society of Surgical Oncology**, 3/98
13. Breast Conservation Therapy for Large Primary and Locally Advanced Breast Cancers After Induction Chemotherapy, **Society of Surgical Oncology**, 3/98
14. Vaccine Implications of a Novel Cytotoxic T Lymphocyte-Recognized Antigen System in Epithelial Cancers, **Third Annual International Vaccine Symposium**, 4/98
15. Vaccine Implications of a New Cytotoxic T Cell (CTL)-Recognized Antigen System Expressed in Multiple Epithelial Cancers, **Gray Wratten Surgical Symposium**, 4/98
16. Vaccine Implications of Folate Binding Protein: A Novel Cytotoxic T Lymphocyte-Recognized Antigen System in Epithelial Cancers, **Society of Biological Therapy**, 10/98
17. Comparison of Dendritic Cell/Peptide-based Vaccines Utilizing HER2/neu and a New Cytotoxic T Cell-Recognized Antigen Expressed in Multiple Epithelial Cancers, **Society of Surgical Oncology**, 3/99
18. Rapid Activation of CTL Effector Function by HER2/neu Peptides Reveals Functionally Distinct Populations in Healthy Donors and Breast Cancer Patients, **Society of Experimental Biology**, 4/99
19. Secretion of CXC Chemokine IP-10 by T Cells from Healthy Donors and Breast Cancer Patients Stimulated with HER2-Peptides: Symposium Presentation, **Texas Immunology Conference**, 11/99

20. The Immune Response to a Folate Binding Protein-Derived Peptide/Dendritic Cell Vaccine in Cancer Patients and Healthy Volunteers, **Society of Surgical Oncology**, 3/00
21. Lymphocytes from Ovarian and Breast Cancer Patients Secrete the Anti-Angiogenic CTC Chemokine IP-10 in Response to Tumor Antigens, **American College of Surgeons**, 10/00
22. T Lymphocytes Synthesize and Export Vascular Growth Factors Related to Heparin-Binding EGF-like Growth Factor (HB-EGF) and Basic Fibroblast Growth Factor (bFGF): Differential Release by CD4⁺ and CD8⁺ Cells, **American Association for Cancer Research**, 11/00
23. HER2/neu Over-Expression in Prostate Cancer Patients Correlates with Clinical Risk Stratification, **Metropolitan Washington Chapter of the American College of Surgeons**, 2/01
24. Axillary Lymph Node Cellular Immune Response to HER2/neu Peptides in Patients with Carcinoma of the Breast, **Society of Surgical Oncology**, 3/01
25. Preclinical Testing of a Peptide-Based, HER2/neu Vaccine in Prostate Cancer, **American Association for Cancer Research**, 3/01
26. Sentinel Lymph Node Evaluation Vaccine in Prostate Cancer is Technically Feasible and May Improve Staging in Colorectal Cancer, **Gary Wratten Surgical Symposium**, 4/01
27. Massive Intra-Abdominal Lipomatous Neoplasm Arising from the Bladder, **Gary Wratten Surgical Symposium**, 4/01
28. The Effect of Changing Gamma Count Threshold on Sentinel Lymph Node Accuracy, **Gary Wratten Surgical Symposium**, 4/01
29. The Use of Turbo PTH in Parathyroid Surgery, **Gary Wratten Surgical Symposium**, 4/01
30. Sentinel Lymph Node Evaluation is Technically Feasible and May Improve Staging in Colorectal Cancer, **Chesapeake Society of Colorectal Surgeons**, 5/01
31. A Comparison of the Immunogenicity of HER2/neu Peptide (E75) and PSA Peptides for the Optimal Vaccine Strategy in Prostate Cancer, **American College of Surgeons**, 10/01
32. Immunosuppressive Drugs Improve Survival of Phyto-Hemoagglutinin (PHA)-Stimulated Lymphocytes but Not Tumor Cell Lines When Exposed to Chemotherapeutic Agents, **American College of Physicians**, 10/01
33. Direct Measurement of Peptide-Specific CD8⁺ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Prostate and Breast Cancer Patients, **Society of University Surgeons Resident's Forum**, 2/02
34. Direct Measurement of Peptide-Specific CD8⁺ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Prostate and Breast Cancer Patients, **Society of Surgical Oncology**, 3/02

35. Evaluation of a HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine (E75) in Prostate and Breast Cancer Patients, **American Association of Cancer Research, Cancer Vaccines Mini-Symposium**, 4/02
36. Optimal Detection of HER2/neu (e75)-Specific CD8 T Cells Using the HLA-A2:Ig Dimer, **American Association of Cancer Research, Cancer Vaccines Mini-Symposium**, 4/02
37. Immunologic Monitoring of Peptide Cancer Vaccine Trial, **Gary Wratten Surgical Symposium**, 4/02
38. Margins in Breast Cancer, **Gary Wratten Surgical Symposium**, 4/02
39. Monitoring the In Vivo Immune Response in Prostate and Breast Cancer Patients Receiving a HER2/neu Vaccine (E75): Evaluation of the HLA-A2:Ig Dimer Assay for the Detection of Vaccine-Specific CD8 T Cells, **8th National Symposium, Basic Aspects of Vaccines**, 5/02
40. Optimal Detection of HER2/neu (E75)-Specific CD8 T Cells Using the HLA-A2:Ig Dimer, **8th National Symposium, Basic Aspects of Vaccines**, 5/02
41. Immunologic Monitoring of Breast and Prostate Cancer Patients Receiving a Preventive HER2/neu Peptide Vaccine, **American Association for Cancer Research "Frontiers in Cancer Prevention Research,"** 10/02
42. Evidence of In Vivo Epitope Spreading in Breast and Prostate Cancer Patients Receiving a HER2/neu Single Peptide Vaccine, **The Keystone Symposium**, 1/03
43. Immunotherapy for Breast Cancer: Clinical Trials and Vaccine Discovery and Development, **National Coalition of Breast Centers Annual Meeting**, 2/03
44. In Vivo Evidence of Epitope Spreading in Breast and Prostate Cancer Patients Receiving a Preventive HER2/neu Peptide Vaccine, **Society of Surgical Oncology**, 3/03
45. In Vivo Peptide-Specific CD8⁺ Clonal Expansion and Epitope Spreading in Breast and Prostate Cancer Patients Receiving a HER2/neu Peptide Vaccine, **American Association for Cancer Research**, 4/03
46. Flow Cytometry Analysis of Viral and Vaccine-Specific CD8 T Cells Using the HLS-A2:Ig Dimer Assay, **American Association of Immunologists**, 5/03
47. In Vivo Evidence of Epitope Spreading in Breast and Prostate Cancer Patients Receiving a Preventive HER2/neu Peptide Vaccine, **Gary Wratten Surgical Symposium**, 5/03
48. Immunological Studies of Vaccine-Specific Responses in Breast and Prostate Cancer Patients Receiving a HER2/neu (E75) Vaccine, **Society of Biological Therapy**, 10/03
49. In Vivo Monitoring of the Immune Response in Breast Cancer Patients Receiving a HER2/neu Peptide Vaccine, **American College of Surgeons**, 10/03

50. In Vivo Expansion of Tumor-Specific CD8⁺ T Cells and Intra-Antigenic Epitope Spreading in Breast Cancer Patients Receiving a Preventive HER2/neu (E75) Peptide Vaccine, **26th Annual San Antonio Breast Cancer Symposium**, 12/03
51. Comparison of Immunological Responses in Node-Positive and Node-Negative Breast Cancer Patients Receiving a HER2/neu E75 Peptide Vaccine, **Society of Surgical Oncology**, 3/04
52. Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High Risk Prostate Cancer Patients, **American Association for Cancer Research**, 3/04
53. Clinical Trial Results of a HER2/neu Peptide (E75) Vaccine in Preventing Recurrence in Node-Positive Breast Cancer Patients, **American Association of Cancer Research**, 3/04
54. Evaluation of the CD107a Cytotoxicity Assay for the Detection of Cytolytic CD8 T Lymphocytes that Recognize HER2/neu Peptides, **American Association of Immunology**, 4/04
55. Direct Comparison of HLA-A2 Dimer and Tetramer Molecules for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine (E75) in Prostate and Breast Cancer Patients, **American Association of Immunology**, 4/04
56. Clinical Trial Results of a HER2/neu Peptide (E75) Vaccine in Preventing Recurrence in Node-Positive Breast Cancer Patients, **Gary Wratten Surgical Symposium**, 4/04
57. Comparison of HLA-A2 Dimer and Tetramer Molecules for the Immunological Monitoring of Breast and Prostate Cancer Vaccine Clinical Trials, **International Congress of Immunology**, 7/04
58. A More Sensitive Immunological Monitoring Tool for Cancer Vaccine Trials: A Direct Comparison of HLA-A2 Dimer and Tetramer Molecules in Measuring the In Vivo Immune Response to a HER2/neu Peptide-Based Vaccine (E75) in Prostate and Breast Cancer Patients, **American College of Surgeons**, 10/04
59. Assessing the Humoral Immune Response in Breast Cancer Patients Receiving a Single Cytotoxic T Lymphocyte Epitope HER2/*neu* Peptide Vaccine, **San Antonio Breast Cancer Symposium**, 12/04
60. The Impact of a Polymorphism in the HER2 Protein on a Peptide Vaccination Strategy, **San Antonio Breast Cancer Symposium**, 12/04
61. Evaluation of the CD107a Cytotoxicity Assay for the Detection of the Cytolytic CD8 T Cells Recognizing HER2/*neu* Vaccine Peptides, **San Antonio Breast Cancer Symposium**, 12/04
62. HER2/neu Peptide Vaccine for High-Risk Prostate Cancer: Initial Insights, **52nd Annual James C. Kimbrough Urological Seminar**, 1/05
63. Immunophenotype Analysis of CD4 and CD8 T Cell Populations Induced by a HER2/neu Peptide (E75) Vaccine in Breast Cancer Patients, **Society of University Surgeons**, 2/05

64. Evidence of In Vivo Intra- and Inter-Antigenic Epitope Spreading in Breast Cancer Patients Receiving a Preventive HER2/neu Peptide Vaccine, **Society of University Surgeons**, 2/05
65. Levels of Circulating Regulatory CD4⁺CD25⁺ T Cells Decreased in Breast Cancer Patients after Vaccination with a HER2/neu (E75) Peptide, **Society of Surgical Oncology**, 3/05
66. Investigation of a Combination of Trastuzumab and HER2 Peptide Vaccines for the Treatment of Breast Cancer, **Society of Surgical Oncology**, 3/05
67. Assessing Serum Cytokine Profiles in Breast Cancer Patients Receiving a HER2/neu Vaccine Using Luminex® Technology, **Society of Surgical Oncology**, 3/05
68. Assessing Serum Cytokine Profiles in Breast Cancer Patients Receiving a HER2/neu Vaccine Using Luminex® Technology, **Metropolitan Washington Chapter of the American College of Surgeons**, 3/05
69. Reduction of Regulatory T Cell Levels and Enhanced Anti-Tumor Immune Responses in Breast Cancer Patients Receiving a HER2 Peptide (E75) Vaccine, **American Association for Cancer Research**, 4/05
70. Serum Cytokine Levels in Breast Cancer Patients Before and After Receiving a HER2/neu Vaccine Assessed Using Multiplex Technology, **American Association for Cancer Research**, 4/05
71. Induction of CD8 T Lymphocytes Specific for the Recognition of a Breast Cancer-Associated Polymorphism in the HER2/neu Protein in a Clinical Trial with the HER2 E75 Peptide Vaccine, **American Association for Cancer Research**, 4/05
72. Immunoprofiling the Cancer-Specific Humoral Immune Response in Sera from Node-Positive and Node-Negative Breast Cancer Patients, **American Association for Cancer Research**, 4/05
73. Inverse Relationship Between Syk and HER2/neu in Breast Epithelial Cancer Cell Lines, **American Association for Cancer Research**, 4/05
74. Correlation of Serum MCP-1 Levels with Clinical Prognostic Variables and Endogenous and Induced Anti-Tumor Immunity in Breast Cancer Patients, **Gary Wratten Surgical Symposium**, 4/05
75. Circulating Regulatory CD4⁺CD25⁺ T Cells, Which Enable Malignant Tumor to Evade the Immune System, Are Present in Higher Levels in Breast Cancer Patients and Are Decreased to Lower, Healthy Patient Levels in Breast Cancer Patients After Vaccination with a HER2/neu Peptide (E75) Vaccine, **Gary Wratten Surgical Symposium**, 4/05
76. Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High Risk Breast Cancer Patients, **American Society of Clinical Oncology**, 5/05
77. Evaluation of the HER2/neu-Derived Peptide GP2 for Use in a Peptide-Based Breast Cancer Vaccine Trial, **American College of Surgeons**, 10/05

78. Correlation of Serum MCP-1 Levels with Clinical Prognostic Variables and Endogenous and Induced Anti-Tumor Immunity in Breast Cancer Patients, **American College of Surgeons**, 10/05
79. Elevated Serum MCP-1 Level is Associated with Favorable Clinical Prognostic Factors and Immune Response and Can be Induced by a HER2/*neu* (E75) Vaccine in Breast Cancer Patients, **San Antonio Breast Cancer Symposium**, 12/05
80. Immunological Monitoring of In Vitro and in Vivo Immune Responses to the Ii-Key/HER2/*neu* MHC Class II Peptide Vaccine in a Phase I Clinical Trial in Breast Cancer Patients, **Academic Surgical Conference/ Society of University Surgeons**, 2/06
81. Phase Ib Trial of the HER2/*neu* Peptide (E75) Vaccine for Optimal Dosing in Node-Negative Breast Cancer Patients, **Academic Surgical Conference/ Society of University Surgeons**, 2/06
82. Comparison of Serum Cytokine Levels in Breast and Prostate Malignancies, **Academic Surgical Conference/Association for Academic Surgery**, 2/06
83. Pattern of Serum Immunoreactivity Against Breast Cancer Cell Lysates May Predict Severity of Disease in Breast Cancer Patients, **Society of Surgical Oncology**, 3/06
84. The Development of a Novel Method to Identify Immunogenic Peptides for Use in Cancer Vaccines, **Society of Surgical Oncology**, 3/06
85. Correlation of ORP150 with Hormone Receptor and Nodal Status in Invasive Breast Cancer, **American Association for Cancer Research**, 4/06
86. Serum-Induced Matrigel Outgrowth of MDA-MB-231 Can Differentiate Between Node-Negative and Node-Positive Breast Cancer Patients, **American Association for Cancer Research**, 4/06
87. Development of a Modified ELISPOT Assay for the Immunological Monitoring of *In Vivo* and *In Vitro* Immune Responses to a HER2/*neu* MHC Class II Peptide Vaccine for Cancer Immunotherapy, **American Association for Cancer Research**, 4/06
88. Luminex Analysis of Serum IL-6, Eotaxin and MCP-1 Levels Can Predict Stage of Disease in Breast Cancer Patients, **American Association for Cancer Research**, 4/06
89. Luminex Analysis of Serum MCP-1, Eotaxin and IL-6 and the Development of a Statistical Model for Predicting Disease Status in Breast Cancer Patients, **Gary P. Wratten Surgical Symposium**, 5/06
90. Immunological Monitoring of Regulatory T Cells by Flow Cytometry in a Novel HLA Class-II HER2/*neu* Peptide Vaccine Clinical Trial in Breast Cancer Patients, **Gary P. Wratten Surgical Symposium**, 5/06
91. Early Results of a Phase I Clinical Trial of an Ii-Key/HER2/*neu* MHC Class II Peptide-Based Vaccine in Breast Cancer Patients, **Gary P. Wratten Surgical Symposium**, 5/06
92. Developing a Predictive Model for Disease Status in Breast Cancer Patients Using Th1 and Th2 Serum Cytokine Profiles, **American Society of Clinical Oncology**, 6/06

93. Early Results of a Phase I Clinical Trial of an Ii-Key/HER2/*neu* MHC Class II Peptide-Based Vaccine in Breast Cancer Patients, **American Society of Clinical Oncology**, 6/06
94. Immunological Monitoring of Regulatory T Cells by Flow Cytometry in a Novel HLA Class-II HER2/*neu* Peptide Vaccine Clinical Trial in Breast Cancer Patients, **American College of Surgeons**, 10/06
95. Early Results of a Phase I Clinical Trial of an Ii-Key/HER2/*neu* MHC Class II Peptide-Based Vaccine in Breast Cancer Patients, **American College of Surgeons**, 10/06
96. Development of Antibody-Targeted Peptide Vaccines as Novel Reagents for Combination Immunotherapy in Cancer Patients, **American College of Surgeons**, 10/06
97. Combined clinical trial results of a HER2/*neu* (E75) vaccine for prevention of recurrence in high-risk breast cancer patients, **San Antonio Breast Cancer Symposium**, 12/06
98. Results of a phase I clinical trial of an Ii-Key/HER2/*neu* MHC class II peptide-based vaccine in breast cancer patients, **San Antonio Breast Cancer Symposium**, 12/06
99. Immune monitoring of CD4⁺CD25⁺FoxP3⁺ regulatory T cells in a novel HLA Class-II HER2/*neu* peptide vaccine clinical trial in breast cancer patients, **Society of Surgical Oncology**, 3/07
100. Quantification and phenotypic characterization of circulating tumor cells (CTCs) for monitoring response to preventative vaccine-based immunotherapy for breast cancer, **Society of Surgical Oncology**, 3/07
101. Assessment of pathologic and immunologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide vaccine. **American Association for Cancer Research**, 4/07
102. Breast cancer patients have different levels of endogenous CD8 T cells capable of recognizing a HER2/*neu* peptide (E75) used as a cancer vaccine in clinical trials. **American Association for Cancer Research**, 4/07
103. Comparing CD4⁺CD25⁺FoxP3⁺ regulatory T cell levels with ex vivo immune assays and clinical delayed type hypersensitivity responses in a novel HLA Class II HER2/*neu* peptide vaccine clinical trial in breast cancer patients. **American Association for Cancer Research**, 4/07
104. Assessment of pathologic and immunologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide vaccine, **Gary Wratten Surgical Symposium**, 5/07
105. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to preventative vaccine-based immunotherapy for breast cancer, **Gary Wratten Surgical Symposium**, 5/07
106. Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with a preventive HER2/*neu* E75-peptide vaccine, **American Society of Clinical Oncology**, 6/07

107. Clinical and immunologic effects of a HER2/*neu* (E75) peptide vaccine booster in previously vaccinated breast cancer patients, **American Society of Clinical Oncology**, 6/07
108. End of Phase II Meeting and Pre-SPA Discussion, **Center for Biologics Evaluation and Research, Food and Drug Administration**, 8/07
109. Pre-clinical and clinical results of a novel Ii-key/HER2/*neu* MHC class II peptide based vaccine in early stage breast cancer (BC) patients, **2nd International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade**, 10/07
110. Intra-antigenic epitope spreading in HLA-A2⁺ breast cancer patients vaccinated with a MHC class I peptide (GP2) derived from the transmembrane region of HER2/*neu*, **International Society for Biological Therapy of Cancer**, 11/07
111. Optimal dose and schedule of a HER2/*neu* peptide (E75) vaccine in disease-free breast cancer patients: Results from two Phase I/II clinical trials, **San Antonio Breast Cancer Symposium**, 12/07
112. Clinical results of a phase I trial of a HER2/*neu*-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients, **San Antonio Breast Cancer Symposium**, 12/07
113. Clinical and immunologic responses of HLA-A3⁺ breast cancer patients vaccinated with the HER2/*neu*-derived peptide vaccine, E75, in a phase I clinical trial, **San Antonio Breast Cancer Symposium**, 12/07
114. Impact of Trastuzumab Treatment on HER2/*neu* Peptide Vaccination-Preliminary Results for a Combination Immunotherapy, **Society of University Surgeons/ Academic Surgical Conference**, 2/08
115. Should thyroid ultrasound be performed on all patients undergoing minimally invasive parathyroid surgery (MIPS)? **Association for Academic Surgery/ Academic Surgical Conference**, 2/08
116. Pathologic and immunologic patterns among breast cancer (BCa) patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide vaccine (E75), **Society of Surgical Oncology**, 3/08
117. Intra-antigenic epitope spreading in HLA-A2⁺ BrCa patients vaccinated with a MHC Class I peptide (GP2) derived from the transmembrane region of HER2/*neu*, **Society of Surgical Oncology**, 3/08
118. Response to a preventive HER2/*neu* peptide (E75) vaccine based on HER2/*neu* status. **American Association for Cancer Research**, 4/08
119. Clinical and immunologic effects of a HER2/*neu* (E75) peptide vaccine booster series in previously vaccinated breast cancer patients. **American Association for Cancer Research**, 4/08
120. Assessment of circulating tumor cells (CTCs) for monitoring immediate and long-term response to primary and booster inoculations with a preventive HER2/*neu* vaccine in breast cancer patients. **American Association for Cancer Research**, 4/08

121. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER2/*neu* peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. **30th Annual Gary Wratten Symposium**, 5/08
122. Assessment of circulating tumor cells (CTCs) for monitoring immediate and long-term response to primary and booster inoculations with a preventative HER2/*neu* vaccine in breast cancer patients. **30th Annual Gary Wratten Symposium**, 5/08
123. Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/*neu* peptide (AE37) vaccine: U.S. Military Cancer Institute Clinical Trials Group Study I-03. **Annual Meeting of the Commission on Cancer**, 10/08
124. Optimal dose and schedule of a HER2/*neu* (E75) peptide vaccine to prevent breast cancer recurrence: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. **Annual Meeting of the Commission on Cancer**, 10/08
125. Phase I trial results of a preventative HER2/*neu* peptide (GP2) vaccine: U.S. Military Cancer Institute Clinical Trials Group Study I-04, **American College of Surgeons**, 10/08
126. Impact of HER2/*neu* booster vaccine to preventative breast cancer recurrence on quantification of circulating tumor cells (CTCs): U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, **American College of Surgeons**, 10/08
127. Optimal method of dosing HER2/*neu* peptide vaccines: from U.S. Military Cancer Institute Clinical Trials Group Study I-01, I-02, I-03, and I-04, **San Antonio Breast Cancer Symposium**, 12/08
128. Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/*neu* peptide (AE37). **San Antonio Breast Cancer Symposium**, 12/08
129. Increased incidence of hormone-receptor negative and basal type breast cancer tumors among HLA-A2⁺ patients and possible implications for cancer vaccine trials: US Military Cancer Institute Clinical Trials Group Study I-01, I-02, I-03, and I-04 . **San Antonio Breast Cancer Symposium**, 12/08
130. Monitoring cytokine levels to adjust dosing and predict response to HER2/*neu* peptide-based cancer vaccines, **Society of University Surgeons/Academic Surgical Conference**, 2/09
131. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine, **Society of Surgical Oncology**, 3/09
132. The HLA-A2 restricted HER2/*neu* derived peptides (E75 and GP2) are both highly immunogenic in HLA-A3 breast cancer patients vaccinated with an E75 vaccine, **American Association for Cancer Research**, 4/09
133. Assessment of circulating tumor cells in disease-free breast cancer patients vaccinated with HER2/*neu* peptide vaccines or immunoadjuvant GM-CSF, **American Association for Cancer Research**, 4/09

134. Correlation of MHC class I and II HLA alleles with the risk of developing breast cancer with aggressive subtypes, particularly ER/PR negative and triple-negative disease, **American Society of Clinical Oncology**, 6/09
135. E6020, a novel immunoadjuvant, is effective at stimulating HER2/neu cancer antigen-specific immunity in healthy donors and breast cancer patients, **International Society for Biological Therapy**, 10/09
136. Interim analysis of a randomized phase II study of the novel HER2/*neu* peptide (GP2) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05, **San Antonio Breast Cancer Symposium**, 12/09
137. Interim analysis of a randomized phase II study of the novel Ii-key hybrid HER2/*neu* peptide (AE37) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05, **San Antonio Breast Cancer Symposium**, 12/09
138. The impact of routine pretreatment magnetic resonance imaging on the surgical planning and outcome in newly diagnosed breast cancer patients, **Academic Surgical Conference**, 2/10
139. Are increased mastectomy rates based on pretreatment MRI findings justified? **Society of Surgical Oncology**, 3/10
140. A modified HER2/*neu* peptide vaccine (2L9V-GP2) demonstrates enhanced CD8+ T cell recognition and stimulation in breast cancer patients at high risk for recurrence, **American Association for Cancer Research**, 4/10
141. Defining regulatory T-cells as CD4+CD25hiCD127- or as CD4+CD25hiFoxP3+ in immune monitoring of cancer vaccine clinical trials, **American Association for Cancer Research**, 4/10
142. Effect of a novel II-key hybrid HER2/*neu* peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations, **American Society of Clinical Oncology**, 6/10
143. Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/*neu*-based peptide vaccines, **American Society of Clinical Oncology**, 6/10
144. Evaluation of a HER2/*neu* and folate binding protein (FBP) peptides in immunotherapy for endometrial cancer, **International Society for Biological Therapy of Cancer**, 9/10
145. Cumulative findings from the E75 peptide vaccine adjuvant trials in breast cancer, **American Society of Clinical Oncology Breast Cancer Symposium**, 10/10
146. Safety and clinical efficacy of multiple booster inoculations with the E75 adjuvant breast cancer vaccine, **San Antonio Breast Cancer Symposium**, 12/10
147. Increased prevalence of HLA-DR3 among breast cancer patients: implications for Her2/*neu* peptide vaccine trials, **San Antonio Breast Cancer Symposium**, 12/10
148. Combination immunotherapy for breast cancer patients: Safety and immunologic data from a phase II trial administering a HER2/*neu*-derived peptide vaccine (AE37+GM-CSF) sequentially

- or concurrently with trastuzumab in the adjuvant setting, **San Antonio Breast Cancer Symposium**, 12/10
149. Vaccine-specific immunologic responses to the novel Ii-Key hybrid HER-2/*neu* peptide (AE37) vaccine in a phase II clinical trial. **Society of Surgical Oncology**, 3/11
 150. Vaccine-specific immunologic responses to the HER-2/*neu* peptide (GP2) vaccine in a prospective, randomized phase II clinical trial. **Society of Surgical Oncology**, 3/11
 151. A prospective, randomized, single-blinded phase II trial evaluating the HER2/*neu* peptide AE37 vaccine in breast cancer patients to prevent recurrence. **33rd Annual Gary Wratten Symposium**, 5/11
 152. A prospective, randomized, single-blinded phase II trial evaluating the HER2/*neu* peptide GP2 vaccine in breast cancer patients to prevent recurrence. **33rd Annual Gary Wratten Symposium**, 5/11
 153. Comparison of in vitro and in vivo immunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/*neu* peptide vaccines GP2 and AE37 in breast cancer patients, **American Association for Cancer Research**, 4/11
 154. Circulating regulatory T cells (CD4⁺CD25^{high}CD127^{low}) decrease in breast cancer patients after vaccination with a modified HER-2/*neu* HLA class II peptide (AE37) vaccine, **American Association for Cancer Research**, 4/11
 155. Sequential administration of trastuzumab and a CD8 T cell-eliciting HER-2/*neu* peptide vaccine in breast cancer patients compared to trastuzumab alone, **Society of Surgical Oncology**, 3/11
 156. Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER-2/*neu* peptide vaccine trial, **Society of Surgical Oncology**, 3/11
 157. The relationship between immunologic response and recurrence in a phase II trial evaluating the HER-2/*neu* peptide vaccines AE37 and GP2 in breast cancer patients in the adjuvant settings, **American College of Surgeons**, 10/11
 158. Vaccination with the HER2-derived E75 peptide vaccine in breast cancer patients may confer greater benefit to patients with less aggressive disease, **Society for Immunotherapy of Cancer**, 11/11
 159. An update of a phase II trial of the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence, **San Antonio Breast Cancer Symposium**, 12/11
 160. Long-term clinical benefit of adjuvant breast cancer vaccine: 5 year efficacy of E75 with multiple booster inoculations, **San Antonio Breast Cancer Symposium**, 12/11
 161. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence, **San Antonio Breast Cancer Symposium**, 12/11

162. Personalized estimates of clostridium difficile infection following colon resection: Using Bayesian Belief Networks (BBNs) to predict perioperative risk, **Pacific Coast Surgical Association Meeting**, 02/12
163. Time-dependent trends in lymph node yield in colon cancer surgery: An international multi-institutional analysis, **Pacific Coast Surgical Association Meeting**, 02/12
164. Booster inoculations safely sustain the immune effects of a CD4-targeted peptide cancer vaccine, **Society of Surgical Oncology 65th Annual Cancer Symposium**, 03/12
165. Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine, **American Association for Cancer Research**, 04/12
166. Immune reconstitution after chemotherapy correlates with increased *in vitro* immune response in breast cancer patients undergoing peptide vaccine therapy, **American Association for Cancer Research**, 04/12
167. An update of a phase II trial of the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence, **Society of Air Force Clinical Surgeons Annual Meeting**, 05/12
168. Long-term clinical benefit of adjuvant breast cancer vaccine: 5 year efficacy of E75 with multiple booster inoculations, **Society of Air Force Clinical Surgeons Annual Meeting**, 05/12
169. An assessment of disease features and immune response in breast cancer patients that recurred after receiving HER2 peptide, AE37 vaccine, in a randomized phase II trial, **34th Annual Gary P Wratten Surgical Symposium**, 05/12
170. From bench to bedside: use of the Ii-Key hybrid technology to improve helper peptides for clinical use in cancer vaccines, **34th Annual Gary P Wratten Surgical Symposium**, 05/12
171. An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial, **American Society of Clinical Oncology Annual Meeting**, 06/12
172. Safety and long-term efficacy of booster inoculations with the E75 peptide vaccine in HER2/*neu*-expressing breast cancer patients, **American Society of Clinical Oncology Annual Meeting**, 06/12
173. From bench to bedside: use of the Ii-Key hybrid technology to improve helper peptides for clinical use in cancer vaccines, **American Society of Clinical Oncology Annual Meeting**, 06/12
174. Bayesian modeling of a thyroid cancer tumor registry to predict outcomes of papillary thyroid cancer (PTC), **American Thyroid Association**, 09/12
175. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple negative breast cancer, **American Society of Clinical Oncology Breast Cancer Symposium**, 09/12
176. Assessment of disease features and immune response in breast cancer patients with recurrence after receiving AE37, a HER2 peptide vaccine, **American College of Surgeons**, 10/12

177. Final results of the phase I/II trials of the E75 adjuvant breast cancer vaccine, **San Antonio Breast Cancer Symposium**, 12/12
178. The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients, **San Antonio Breast Cancer Symposium**, 12/12
179. Pure flat epithelial atypia (PFEA): Excise or observe, **Society of Surgical Oncology**, 03/13
180. Factors associated with recurrence in breast cancer patients vaccinated with the HER2-derived GP2 vaccine, **Society of Surgical Oncology**, 03/13
181. Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor- α (FR α), **Society of Surgical Oncology**, 03/13
182. Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor-alpha, **American Association for Cancer Research**, 04/13
183. Delayed urticarial reactions in the phase II trial of HER2/neu peptide vaccines + GM-CSF vs. GM-CSF alone in high risk breast cancer patients, **American Association for Cancer Research**, 04/13
184. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting, **American Society of Clinical Oncology**, 05/13
185. Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence, **American Society of Clinical Oncology**, 05/13
186. Randomized phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: A planned interim analysis, **American Society of Clinical Oncology**, 05/13
187. Biomarker correlation to clinical response in phase I/II trials of the adjuvant breast cancer vaccine neuvax (nelipepimut-S or E75), **American Society of Clinical Oncology**, 05/13
188. Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37), **American College of Surgeons**, 10/13
189. Predicting Clinical Benefit after Completion of Treatment with the Adjuvant Breast Cancer (BCa) Vaccine, NeuVax (Neli-pepimut-S or E75), **American College of Surgeons**. 10/ 2013.
190. Preliminary results for the phase I trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients, **Society for Immunotherapy of Cancer**, 11/13
191. Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients, **Society for Immunotherapy of Cancer**, 11/13

192. HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials, **San Antonio Breast Cancer Symposium**, 12/13
193. Preliminary results for the phase I trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients, **San Antonio Breast Cancer Symposium**, 12/13
194. Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence, **San Antonio Breast Cancer Symposium**, 12/13
195. Induced immunity correlates with and may predict clinical benefit in the phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients, **Society of Surgical Oncology**, 03/14
196. The clinical benefit and safety of boosting the HER2 peptide vaccine (GP2+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence, **Society of Surgical Oncology**, 03/14
197. Phase I Trial Results of a Folate Receptor Alpha-directed Cancer Vaccine (E39) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence, **Society of Gynecologic Oncology**, 3/14
198. The impact of routine pretreatment magnetic resonance imaging on the surgical planning and outcome in newly diagnosed breast cancer patients, **SAGES**, 4/14
199. Folate Binding Protein (FBP) Vaccine in Breast and Ovarian Cancer Patients, **SAGES**, 4/14
200. An Attenuated Version of a Strongly Immunogenic, Peptide-based Vaccine to Enhance an Anti-cancer Immune Response Against Folate Receptor Alpha, **SAGES**, 4/14
201. Immunologic effects of a HER2 peptide (GP2) vaccine booster in previously vaccinated breast cancer patients, **American Association for Cancer Research**, 04/14
202. HLA-A2 and HER2 expression levels as clinical prognostic factors in breast cancer patients: Implications for peptide cancer vaccine trials, **American Association for Cancer Research**, 04/14
203. Comparison of recurrent and non-recurrent breast cancer patients undergoing AE37 peptide vaccine therapy, **American Society of Clinical Oncology**, 05/14
204. Comparison of recurrent and non-recurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy, **American Society of Clinical Oncology**, 05/14
205. Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine vs GM-CSF alone administered in the adjuvant setting to high risk breast cancer patients, **American Society of Clinical Oncology**, 05/14
206. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine vs GM-CSF alone administered in the adjuvant setting to high risk breast cancer patients, **ASCO Breast Symposium**, 9/14
207. Biomarker Correlation to Clinical Response in a Phase II Trial of the HER2 Peptide Vaccine (AE37+GM-CSF), **American College of Surgeons**, 10/14

208. Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence, **American College of Surgeons**, 10/14
209. Correlation of HER2/neu Antibody Response to Clinical Response in a Phase II Trial of the AE37+GM-CSF HER2 Peptide Vaccine, **Society of Immunotherapy for Cancer**, 11/14
210. Preliminary Results of the Phase IIa Trial of a Folate Binding Protein (FBP) Adjuvant Cancer Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence, **Society of Immunotherapy for Cancer**, 11/14
211. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence, **San Antonio Breast Cancer Symposium**, 12/14
212. Results of a phase Ib trial of combination immunotherapy with HER2–derived peptide vaccine GP2+GM-CSF and trastuzumab in breast cancer patients, **Society of Surgical Oncology**, 3/15
213. A Phase I/IIa Clinical Trial of an Autologous Tumor/Dendritic Cell Fusion (Dendritoma) Vaccine with Low Dose Interleukin-2 in Stage IV Melanoma, **Society of Surgical Oncology**, 3/15
214. Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine, **American Association for Cancer Research**, 4/15
215. Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence, **American Society of Clinical Oncology**, 5/15
216. Final Pre-specified Analysis of the Phase II Trial of the AE37+GM-CSF Vaccine in High Risk Breast Cancer Patients to Prevent Recurrence. **American Society of Clinical Oncology**, 5/15
217. Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence, **European Society of Medical Oncology**, 9/15
218. Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients, **European Society of Medical Oncology**, 9/15
219. Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles + dendritic cells vaccine (TLPLDC) in patients with solid tumors, **International Conference on Immunotherapy of Cancer**, 9/15
220. Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of GP2+GM-CSF HER2 peptide vaccine, **American College of Surgeons**, 10/15
221. DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine., **Society of Immunotherapy for Cancer**, 11/15

222. Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine, **Society of Immunotherapy for Cancer**, 11/15
223. Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients, **Society of Immunotherapy for Cancer**, 11/15
224. Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence, **San Antonio Breast Cancer Symposium**, 12/15
225. Impact of Boosting in the Phase II Trial of the AE37+GM-CSF Vaccine in High Risk Breast Cancer Patients to Prevent Recurrence, **Society of Surgical Oncology**, 3/16
226. Efficacy of Booster Inoculations in a Phase II Trial of GP2, a HER2-Derived Peptide Vaccine, for the Prevention of Breast Cancer Recurrence, **Society of Surgical Oncology**, 3/16
227. Correlation between pre-existing immunity and clinical response in a phase II trial using HER2 based peptide vaccines to prevent breast cancer recurrence, **Society of Surgical Oncology**, 3/16
228. Comparing an attenuated booster (E39') vs E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients, **American Association for Cancer Research**, 4/16
229. The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, GALE-301 (E39) + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence, **American Society of Clinical Oncology**, 6/2016
230. Initial Phase I/IIa Trial Results of an Autologous Tumor Lysate, Particle-Loaded, Dendritic Cell (TLPLDC) Vaccine in Patients with Solid Tumors, **American Society of Clinical Oncology**, 6/2016

PUBLICATIONS

MANUSCRIPTS

1. Magnuson TH, Lillemoe KD, Peoples GE, Pitt HA. Oral calcium promotes pigment gallstone formation. **J Surg Res** 1989;46:286-91.
2. Lillemoe KD, Magnuson TH, High RC, Peoples GE, Pitt HA. Caffeine prevents cholesterol gallstone formation. **Surgery** 1989;106:400-6.
3. Andrews JVR, Schoof DD, Bertagnolli MM, Peoples GE, Goedegebuure PS, Eberlein TJ. Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. **J Immunother** 1993;14:1-10.
4. Peoples GE, Schoof DD, Andrews JVR, Goedegebuure PS, Eberlein TJ. T cell recognition of ovarian cancer. **Surgery** 1993;114:227-34.
5. Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JVR, Richie J, Eberlein TJ. CD4⁺ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. **Cell Immunol** 1993;150:114-23.

6. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. **J Immunol** 1993;151:5481-91.
7. Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ. T cell receptor V β 2 and V β 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. **J Immunol** 1993;151:5472-80.
8. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of HER2/neu expression with sensitivity to tumor-specific cytotoxic T cells in human ovarian cancer. **J Immunol** 1994;152:2393-2400.
9. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export vascular cell heparin-binding EGF-like growth factor (HB-EGF) and basic fibroblast growth factor (bFGF): Differential production and release by CD4⁺ and CD8⁺ T cells. **Proc Natl Acad Sci USA** 1994;91:2890-5.
10. Peoples GE, Yoshino I, Douville C, Andrews JVR, Goedegebuure PS, Eberlein TJ. TCR V β 3⁺ and V β 6⁺ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2⁺ ovarian cancers. **J Immunol** 1994;152:4993-9.
11. Goedegebuure PS, Lee KY, Matory YL, Peoples GE, Yoshino I, Eberlein TJ. Classification of CD4⁺ T helper cell clones in human melanoma. **Cell Immunol** 1994; 156:170-179.
12. Yoshino I, Peoples GE, Goedegebuure PS, DiMaio JM, Gazdar AF, Eberlein TJ. HER2/neu-derived peptide(s) are shared antigens among human non-small cell lung cancer and ovarian cancer. **Cancer Res** 1994;54:3387-90.
13. Yoshino I, Goedegebuure PS, Peoples GE, Lee KY, Eberlein TJ. Human tumor-infiltrating CD4⁺ T cells react to B cell lines expressing heat shock protein 70. **J Immunol** 1994;153:4149-58.
14. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. **Proc Natl Acad Sci USA** 1995;92:432-6.
15. Linehan DC, Peoples GE, Parikh AS, Goedegebuure PS, Eberlein TJ. In vitro stimulation of ovarian tumor-associated lymphocytes with a HER2/neu-derived peptide enhances tumor cytotoxicity. **Surg Oncol** 1995;4:41-9.
16. Peoples GE, Blotnick S, Freeman MR, Klagsbrun M, Eberlein TJ. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce HB-EGF and bFGF: a potential pathologic role. **Proc Natl Acad Sci USA** 1995;92:6547-51.
17. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ. Shared T cell epitopes in epithelial tumors. **Cell Immunol** 1995;164:279-86.
18. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad G, Peoples GE, Klagsbrun M. Peripheral blood lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. **Cancer Res** 1995;55:4140-5.

19. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytotoxicity by tumor associated lymphocytes in human metastatic breast cancer. **J Immunol** 1995;155:4486-91.
20. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG. Ovarian cancer-associated lymphocyte recognition of folate binding protein (FBP) peptides. **Ann Surg Oncol** 1998;5:743-50.
21. Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FA, Buchholz TA, Strom EA, McNeese MD, Hunt KK. Feasibility of breast conservation therapy (BCT) in metachronous or synchronous bilateral breast cancer. **Ann Surg Oncol** 1998;6:102-8.
22. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Wong S, Wharton JT, Kim J-W, Ioannides CG. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. **Anticancer Res** 1999;19:1-10.
23. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG. Vaccine implications of a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. **Clin Cancer Res** 1999;5:4214-23.
24. Lee TV, Castilleja A, Peoples GE, Kim D-K, Murray JL, Gershenson DM, Ioannides CG. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. **J Interferon Cytokine Res** 2000;20:391-401.
25. Lee TV, Anderson BW, Peoples GE, Castilleja A, Murray JL, Gershenson DM, Ioannides CG. Identification of activated tumor antigen reactive CD8⁺ cells in healthy individuals. **Oncol Rep** 2000;7:455-66.
26. Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. **Clin Cancer Res** 2000;6:4192-4200.
27. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Curley SA, Skibber JM. Quality of life and cost-effectiveness analysis of therapy for locally recurrent rectal cancer. **Dis Colon Rectum** 2000;43:1695-1701.
28. Rehrig ST, Marshall S, Meghoo C, Peoples GE, Shriver CD. Five-year qualitative results of isolated cryosurgical ablation for hepatic malignancy at Walter Reed Army Medical Center. **Curr Surg** 2001;58:81-5.
29. Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Axillary lymph node cellular immune response to HER2/neu peptides in patients with carcinoma of the breast. **J Interferon Cytokine Res** 2002;22:583-92.
30. Cox ED, Kellicut D, Adair C, Marley K, Otchy D, Peoples GE. Sentinel lymph node evaluation is technically feasible and may improve staging in colorectal cancer. **Curr Surg** 2002;59:301-6.

31. Hueman MT, Scanlan BJ, White PW, Golarz SR, Peoples GE, Shriver CD, Maniscalco-Theberge ME. The effect of changing gamma count threshold on sentinel lymph node accuracy. **Curr Surg** 2002;59:313-17.
32. Ward DT, Swiecki CW, Peoples GE. Massive intra-abdominal lipomatous neoplasm arising from the bladder. **Curr Surg** 2002;59:299-301.
33. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccines targeting breast cancer. **Clin Cancer Res** 2003;9:3222-34.
34. Peoples GE, Arciero CA, Shriver CD. Reports from the tumor board: Presentations from the Walter Reed Army Medical Center, Part I. **Oncology** 2003;17:1494-1502.
35. Peoples GE, Arciero CA, Adair C, Shriver CD. Reports from the tumor board: Presentations from the Walter Reed Army Medical Center, Part II. **Oncology** 2004;18:140-2.
36. Peoples GE, Arciero CA, Shriver CD. Reports from the tumor board: Presentations from the Walter Reed Army Medical Center, Part III. **Oncology** 2004;18:437-8, 440.
37. Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Direct measurement of peptide specific CD8⁺ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. **J Clin Immunol** 2004;24:449-61.
38. Arciero CA, Peoples GE, Stojadinovic A, Shriver CD. The utility of a rapid parathyroid assay for uniglandular, multiglandular and recurrent parathyroid disease. **Am Surg** 2004;70:588-92.
39. Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan I, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. **Intl J Oncol** 2004;25:1769-80.
40. Peoples GE, Jezior JR, Shriver CD. From the war zone to the United States: Caring for the wounded in Iraq – A photo essay. **N Engl J Med** 2004;351:2476-80.
41. Peoples GE, Gerlinger T, Budinich C, Burlingame B. The most frequently requested pre-combat refresher training by the special forces medics during Operation Enduring Freedom. **Mil Med** 2005;170:31-7.
42. Stojadinovic A, Fields SI, Shriver CD, Lenington S, Ginor R, Peoples GE, Burch HB, Peret T, Freund HR, Nissan A. Electrical impedance scanning of thyroid nodules prior to thyroid surgery: A prospective study. **Ann Surg Oncol** 2005;2:152-60.
43. Kawano K, Efferson CL, Peoples GE, Murray JL, Ioannides CG. Sensitivity of undifferentiated, high-TCR-density CD8⁺ cells to a single methylene group appended to tumor antigen determines their differentiation or death. **Cancer Res** 2005;65:2930-7.
44. Peoples GE, Gerlinger T, Craig RM, Burlingame B. The 274th Forward Surgical Team experience during Operation Enduring Freedom. **Mil Med** 2005;170:451-9.

45. Peoples GE, Gerlinger T, Craig RM, Burlingame B. Combat casualties in Afghanistan cared for by a single Forward Surgical Team during the initial phases of Operation Enduring Freedom. **Mil Med** 2005;170:462-8.
46. Mittendorf MA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8⁺ cells recognizing HER2/*neu* vaccine peptides. **Br Cancer Res Treat** 2005;92:85-93.
47. Stojadinovic A, Allen PJ, Protic M, Potter JF, Shriver CD, Nelson JM, Peoples GE. Colon sentinel lymph node mapping: practical surgical applications. **J Am Coll Surg** 2005;201:297-313.
48. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S. Clinical trial results of a HER2/*neu* (E75) vaccine to prevent recurrence in high risk breast cancer patients. **J Clin Oncol** 2005;23:7536-45.
49. Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Moul JW, Ioannides CG, Ponniah S, Peoples GE. Phase I of a HER-2/*neu* peptide (E75) for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. **Clin Cancer Res** 2005;11:7470-9.
50. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Correlations between serum MCP-1 levels, clinical prognostic factors, and HER2/*neu* vaccine-related immunity in breast cancer patients. **Clin Cancer Res** 2006;12:478-86.
51. Khoo S, Ponniah S, Peoples GE. HER2/*neu* vaccines in breast cancer. **Women's Health (Lond Engl)** 2006;2:217-23.
52. Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/*neu* peptide induces intra- and inter-antigenic epitope spreading in early stage breast cancer patients. **Surgery** 2006;139:407-18.
53. McLeod IK, Arciero CA, Noordzij JP, Stojadinovic A, Peoples GE, Melder PC, Langley R, Bernet V, Shriver CD. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia following total or completion thyroidectomy. **Thyroid** 2006;16:259-65.
54. Vertrees A, Kellicut D, Ottman S, Peoples G, Shriver CD. Early definitive abdominal closure using serial closure technique on injured soldiers returning from Afghanistan (Operation Enduring Freedom) and Iraq (Operation Iraqi Freedom). **J Am Coll Surg** 2006;202:762-72.
55. Mittendorf EA, Storrer CE, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Evaluation of the HER2/*neu*-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. **Cancer** 2006;106:2309-17.
56. Craig RM and Peoples GE. A novel device developed, tested, and utilized for warming and maintaining IV fluids in the Forward Surgical Team during Operation Enduring Freedom. **Mil Med** 2006;171:500-3.

57. Hueman MT, Stojadinovic A, Storrer CE, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Levels of circulating regulatory CD4⁺CD25⁺ T cells are decreasing in breast cancer patients after vaccination with a HER2/*neu* peptide (E75) vaccine. **Br Cancer Res Treat** 2006;98:17-29.
58. Stojadinovic A, Auton A, Peoples GE, McKnight GM, Shields C, Croll SM, Bleckner LL, Winkley J, Maniscalco-Theberge ME, Buckenmaier III CC. Responding to challenges in modern combat casualty care: Innovative use of advanced regional anesthesia. **Pain Med** 2006;7:330-8.
59. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/*neu* peptide vaccines for the treatment of breast cancer. **Ann Sur Oncol** 2006;13:1085-98.
60. Mittendorf EA, Peoples GE. HER2/*neu* peptide breast cancer vaccines: Current status and future directions. **Breast Diseases: A Year Book Quarterly** 2007;17:318-20.
61. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney J, Shriver CD, Ponniah S, Peoples GE. Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/*neu* peptide (E75) and GM-CSF vaccine. **Cancer Immun Immunoth** 2007;56:135-46.
62. Dehqanzada ZA, Storrer CE, Hueman MT, Foley R, Harris K, Shriver CD, Ponniah S, Peoples GE. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/*neu* vaccine using Luminex® technology. **Oncol Rep** 2007;17:687-94.
63. Stojadinovic A, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard RS, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, Peretz T, Peoples GE. Prospective randomized study comparing sentinel lymph node evaluation with standard pathological evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. **Ann Surg** 2007;245:846-57.
64. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? **Cancer** 2007;110:1677-86.
65. Stojadinovic A, Henry LR, Peoples GE, Mittendorf EA, Lenington S, Nissan A, Shriver CD. Satisfaction with breast cancer screening and future screening participation. **Med Sci Monit** 2007;13:CR422-9.
66. Schaden W, Thiele R, Kolpl C, Pusch M, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, Stojadinovic A. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. **J Surg Res** 2007;143:1-12.
67. Hamsher C, Smith A, Dehqanzada ZA, Khoo S, Shriver CD, Ponniah S, Peoples GE, and Moroni M. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients. **Cancer Immun Immunoth** 2007;56:1711-21.
68. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao Tzu-Cheg, Ponniah S, Peoples GE, Moroni M. HYOU1/Orp150 expression in breast cancer. **Med Sci Monit** 2007;13:BR231-9.

69. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/*neu* vaccine-based immunotherapy for breast cancer. **Ann Surg Oncol** 2007;14:3359-68.
70. Amin A, Shriver CD, Henry LR, Lenington S, Peoples GE, Stojadinovic A. Breast cancer screening compliance among young women in a free access healthcare system. **J Surg Oncol** 2008;97:20-4.
71. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Combined clinical trial results of a HER2/*neu* (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-01&I-02. **Clin Cancer Res** 2008;14:797-803.
72. Nissan A, Peoples GE, Abu-Wassal B, Adair CF, Prus D, Howard RS, Lenington SG, Fields SI, Freund HR, Peretz T, Burch HB, Shriver CD, Stojadinovic S. Prospective trial evaluating electrical impedance scanning of thyroid nodules prior to thyroidectomy: final results. **Ann Surg** 2008;247:843-53.
73. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel li-key hybrid preventive HER2/*neu* peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. **J Clin Oncol** 2008; 26: 3426-33.
74. Gates JD, Benavides LC, Stojadinovic A, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrills GA, Ponniah S, Peoples GE. Monitoring circulating tumor cells in cancer vaccine trials. **Hum Vaccin** 2008;4:389-92.
75. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/*neu* peptide vaccine. **Cancer Immunol Immunoth** 2008;57:1511-21.
76. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Optimal dose and schedule of a HER2/*neu* (E75) peptide vaccine in disease-free breast cancer patients. **Cancer** 2008;113:1666-75.
77. Amin A, Benavides LC, Holmes JP, Gates JD, Hueman MT, Carmichael MG, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Assessment of immunologic response and pathologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide (E75) vaccine. **Cancer Immunol Immunoth** 2008;57:1817-25.
78. Mittendorf EA, Holmes JP, Murray JL, Peoples GE. CD4+ T cells in antitumor immunity: utility of an li-Key hybrid preventive HER2/*neu* peptide (AE37) vaccine. **Expert Opin Biol Ther** 2009;9:71-8.
79. Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG. Distinct patient responses to activation of T cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-

- 788)] peptides could lead to development of personalized cancer vaccines. **Anticancer Res** 2009;29:41-58.
80. Clifton GT, Peoples GE. Overcoming cancer immune tolerance and escape. **Clin Cancer Res** 2009;15:749-51.
 81. Gates, JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE. Long-term follow-up assessment of a HER2/*neu* peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients. **J Am Coll Surg** 2009;208:193-201.
 82. Davis TA, Stojadinovic A, Anam K, Amare M, Naik S, Peoples GE, Tadaki D, Elster EA. Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. **Int Wound J** 2009;6:11-12.
 83. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa S. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. **Cancer Epidem Biomarkers Prev** 2009;18:784-91.
 84. Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. The impact of HER2/*neu* expression level on response to the E75 Vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. **Clin Cancer Res** 2009;15:2895-904.
 85. Zhu K, Devesa SS, Wu H, Zahm SH, Jatoi I, Anderson WF, Peoples G, Maxwell LG, Granger E, Potter JF, McGlynn K. Cancer incidence in the U.S. military population: comparison with rates from the SEER program. **Cancer Epidemiol Biomarkers Prev** 2009;18:1740-5.
 86. Stojadinovic A, Elster E, Potter BK, Davis TA, Tadaki DK, Brown TS, Ahlers S, Attinger CE, Anderson RC, Burris D, Centeno J, Champion H, Crumbley DR, Denobile J, Duga M, Dunne JR, Eberhardt J, Ennis WJ, Forsberg JA, Hawksworth J, Helling TS, Lazarus GS, Milner SM, Mullick FG, Owner CR, Pasquina PF, Patel CR, Peoples GE, Nissan A, Ring M, Sandberg GD, Schaden W, Schultz GS, Scofield T, Shawen SB, Sheppard FR, Stannard JP, Weina PJ, Zenilman JM. Combat Wound Initiative program. **Mil Med** 2009; 175:18-24.
 87. Matsueda S, Gao H, Efferson CL, Tsuda N, Ishiyama S, Li Y, Ioannides MG, Fisk B, Peoples GE, Ioannides CG. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. **Anticancer Res** 2009;29:2427-35.
 88. Mine T, Ferrone S, Vlastos G, Peoples GE, Ioannides CG. Working hypothesis: Elimination of cancer stem cells in solid tumors by immuno-gene therapy using cancer vaccines and created-inhibitory RNA. **Curr Cancer Ther Rev** 2009;5:217-26.
 89. Gates JD, Benavides LC, Shriver CD, Peoples GE, Stojadinovic S. Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy? **J Surg Res** 2009; 155:254-60.
 90. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A. Development of a clinical decision model for thyroid nodules. **BMC Surg** 2009;9:12.

91. Stojadinovic A, Peoples GE, Jurgens JS, Howard RS, Schuyler B, Kwon KH, Henry LR, Shriver CD, Buckenmaier CC. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomized controlled trial. **Lancet Oncol** 2009;10:849-54.
92. Shumway NM, Mittendorf EA, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new immunotherapeutic strategy for early-stage disease. **BioDrugs** 2009;23:277-87.
93. Hoy AJ, Peoples GE, McLennan PL. The effect of vasoconstrictors on oxygen consumption in resting and contracting skeletal muscle of the autologous pump-perfused rat hindlimb. **J Physiol Pharmacol** 2009;60:155-60.
94. Peoples GE. HER2 vaccination in high-risk breast cancer. **Clin Adv Hematol Oncol** 2009;7:715-17.
95. Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the HER-2/*neu* peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study 1-04. **Cancer** 2010;116:292-301.
96. Nissan A, Protic M, Bilchik A, Eberhardt J, Peoples GE, Stojadinovic A. Predictive model of outcome of targeted nodal assessment in colorectal cancer. **Ann Surg** 2010;251:265-74.
97. Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE. Clinical and immunologic responses of HLA-A3⁺ breast cancer patients vaccinated with the HER2/*neu*-derived peptide vaccine, E75, in a phase I/II clinical trial. **J Am Coll Surg** 2010;210:140-7.
98. Stojadinovic A, Eberhardt C, Henry L, Berhardt J, Elster EA, Peoples GE, Nissan A, Shriver CD. Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. **ePlasty** 29 March 2010, http://www.eplasty.com/index.php?option=com_content&view=article&id=429&catid=15&Itemid=116
99. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Pappamichail M, Baxevanis CN. A new era in anticancer peptide vaccines. **Cancer** 2010;116:2071-80.
100. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? **Exp Rev Vaccines** 2010;9:519-25.
101. Clifton T, Pappas JA, Pavlik M, Papay D, Holmes JP, Ponniah S, Peoples GE. Cancer Vaccine Development Program Collaborations. **Mil Med** 2010;175 (7 Suppl):54-6.
102. Zhou J, Enewold L, Stojadinovic A, Clifton GT, Potter JF, Peoples GE, Zhu K. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. **Cancer Causes Control** 2010;21:853-61.

103. Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminated CD44 Hi progenitors of taxol-resistant ovarian cancer cells. **Oncol Rep** 2010;23:1537-43.
104. Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, Stojadinovic A. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. **Ann Surg** 2010;252:467-76.
105. Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4⁺CD25⁺FOXP3⁺) decrease in breast cancer patients after vaccination with a modified MHC class I HER2/*neu* (AE37) peptide. **Vaccine** 2010;28:7476-82.
106. Zhou J, Enewold L, Peoples GE, Clifton GT, Potter JF, Stojadinovic A, Zhu K. Trends in cancer screening among Hispanic and white non-Hispanic women, 2000-2005. **J Womens Health** 2010;19:2167-74.
107. Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. **Cancer** 2011;117:463-17.
108. Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S, Peoples GE. Folate receptor α : a storied past and promising future in immunotherapy. **Hum Vaccin** 2011;7:183-90.
109. Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Comparison of different HER2/*neu* vaccines adjuvant breast cancer clinical trials: implications for dosing of peptide vaccines. **Expert Rev Vacc** 2011;10:201-10.
110. Li Y, Efferson CL, Ramesh R, Peoples GE, Hwu P, Ioannides CG. A peptidoglycan monomer with the glutamine to serine change and basic peptides bind *in silico* to TLR-2 (403-455). **Cancer Immunol Immunother** 2011;60:515-24.
111. Zhou J, Enewold L, Peoples GE, McLeod DG, Potter JF, Steele SR, Clive KS, Stojadinovic A, Shu K. Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005. **J Natl Med Assoc** 2011;103:343-50.
112. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. **Expert Rev Vacc** 2011;10:755-74.
113. Steele SR, Chen SL, Stojadinovic A, Nissan A, Zhu K, Peoples GE, Bilchik A. The impact of age on quality measure adherence in colon cancer. **J Am Coll Surg** 2011;213:95-103.
114. Enewold LR, Zhou J, Devesa SS, Berrington de Gonzalez, A, Anderson WF, Zahm SH, Stojadinovic A, Peoples GE, Marrogi AJ, Potter JF, McGlynn KA, Zhu K. Thyroid cancer

- incidence among active duty U.S. military personnel, 1990-2004. **Cancer Epidemiol Biomarkers Prev** 2011;20:2369-76.
115. Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. **Expert Opin Biol Ther** 2011;11:1543-50.
 116. Barchie MF, Clive KS, Tyler JA, Sutcliffe JB, Kirkpatrick AD, Bell LM, Banks KP, Belenkiy S, Saenger JS, Peoples GE. Standardized pretreatment breast MRI – accuracy and influence on mastectomy decisions. **J Surg Oncol** 2011;104:741-5.
 117. Vreeland TJ, Hale DF, Clifton GT, Sears AK, Mittendorf EA, Peoples GE. Peptide vaccine strategies in the treatment of cancer. **J Proteomics Bioinform** 2013 Apr 25;6(4):081-84.
 118. Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK, Zeiger MA, Stojadinovic A. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. **J Cancer** 2012;3:1-6.
 119. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-01. **Cancer** 2012;118:2594-602.
 120. Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA. The GP2 peptide: a HER2/*neu*-based breast cancer vaccine. **J Surg Oncol** 2012;105:452-8.
 121. Stojadinovic A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard RS, Steele SR, Peoples GE, Bilchik A. Time-dependent trends in lymph node yield and impact on adjuvant therapy decisions in colon cancer surgery: an international multi-institutional study. **Ann Surg Oncol** 2012;19:4178-85.
 122. Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA. Cancer vaccines: should we be targeting patients with less aggressive disease? **Expert Rev Vaccines** 2012;11:721-31.
 123. Nissan A, Protic M, Bilchik AJ, Howard RS, Peoples GE, Stojadinovic A. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) randomized controlled trial comparing targeted nodal assessment and ultrastaging to standard pathological evaluation for colon cancer. **Ann Surg** 2012;256:412-27.
 124. Stojadinovic S, Bilchik A, Smith D, Eberhardt JS, Ward EB, Nissan A, Johnson EK, Protic M, Peoples GE, Avital I, Steele SR. Clinical decision support and individualized prediction of survival in colon cancer: bayesian belief network model. **Ann Surg Oncol** 2013;20:161-74.
 125. Arciero CA, Henry LR, Howard RS, Peoples GE, Bilchik A, Avital I, Buckenmaier CC, Stojadinovic S. Technical effects of adding 1% lidocaine to technetium sulfur colloid for sentinel lymphatic mapping in early breast cancer: Analysis of data from a double-blind randomized controlled trial. **Ann Surg Oncol** 2013;20(6):511-23.

126. Peoples GE. Rethinking cancer vaccines to avoid T-cell traps. **Immunotherapy** 2013;5(7):665-8.
127. Potter BK, Hwang PF, Forsberg JA, Hampton CB, Graybill JC, Peoples GE, Stojadinovic A. Impact of margin status and local recurrence on soft-tissue sarcoma outcomes. **J Bone Joint Surg Am** 2013;95(20):e151.
128. Stojadinovic A, Avital I, Wallace TJ, Peoples GE, Steele S. Special issue on current challenges and future directions in monitoring responses after treatment of primary cancer. **J Cancer** 2014;5(1):1-2.
129. Graham LJ, Shupe MP, Schneble EJ, Flynt FL, clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, Peoples GE, Shumway NM. Current approaches and challenges in monitoring treatment responses in breast cancer. **J Cancer** 2014;5(1):58-68.
130. Shupe MP, Graham LJ, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Stojadinovic A, Peoples GE, Shumway NM. Future directions for monitoring treatment responses in breast cancer. **J Cancer** 2014;5(1):69-78.
131. Perez SA, Peoples GE, Papamichail M, Baxevanis CN. Invariant chain-peptide fusion vaccine using HER-2/neu. **Methods Mol Biol** 2014;1139:321-36.
132. Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF. Current approaches and challenges in early detection of breast cancer recurrence. **J Cancer** 2014;5(4):281-290.
133. Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF. Future directions for early detection of recurrent breast cancer. **J Cancer** 2014;5(4):291-300.
134. Schneble EJ, Yu X, Wagner T, Peoples GE. Novel dendritic cell-based vaccination in late stage melanoma. **Hum Vaccin Immunother** 2014;10(11): [Epub ahead of print].
135. Schneble EJ, Berry JS, Trappey FA, Clinton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. **Immunotherapy** 2014 May;6(5):519-31.
136. Mittendorf EA, Clinton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. **Ann Oncol** 2014 Sep;25(9):1735-42.
137. Clifton, GT, Mittendorf EA, Peoples GE. Adjuvant HER2/neu Peptide Cancer Vaccines in Breast Cancer. **Immunotherapy**, November 2015; 7 (11):1159-1168
138. Clifton GT, Kohrt HE, Peoples GE. Critical issues in cancer vaccine trial design. **Vaccine**. 2015 Dec 16;33(51):7386-92.
139. Berry JS, Trappey AF, Vreeland TJ, Pattyn AR, Clifton GT, Berry EA, Schneble EJ, Kirkpatrick AD, Saenger JS, Peoples GE. Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial

Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation. **J Cancer** 2016; 7(1):1-6.

140. Greene, JM, Schneble, EJ, Jackson, DO, Hale, DF, Vreeland, TJ, Flores, M, Martin, J, Garth, HS, Hardin, MO. A Phase I/IIa Clinical Trial in Stage IV Melanoma of An Autologous Tumor – Dendritic Cell Fusion (Dendritoma) Vaccine with Low Dose Interleukin-2. **Cancer Immunol Immunoth**, 2016 April;65(4): 383-392.
141. Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. **J Immunother Cancer**. 2016 Mar 15;4:15.
142. Mittendorf, EA, Ardavanis, A, Symanowski, J, Murray, JL, Shumway, NM, Litton, JK, Hale DF, Perez, SA, Anastasopoulou, EA, Pistamaltzian, NF, Ponniah, S, Baxevanis, CN, Von Hofe, E, Papamichail, M, Peoples GE. Primary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence. **Ann Oncol** 2016 March 30 [Epub ahead of print].
143. Clifton, GT, Peoples GE, Mittendorf, EA. The Development and Use of the E75 (HER2 369-377) Peptide Vaccine. **Future Oncol**, 2016 April [Epub ahead of print].
144. Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-Based Cancer Vaccine Strategies and Clinical Results. **Methods Mol Biol**. 2016;1403:797-817.

ABSTRACTS

1. Magnuson TH, Lillemoen DK, Peoples GE, Li L, Pitt HA. Estrogen alters biliary calcium metabolism and induces pigment sludge. **Surg Forum** 1988;39:154-5.
2. Terashima Y, Peoples GE, Schoof DD, Richie J, Eberlein TJ. Cytokine production and cytotoxic function by T-lymphocyte clones from renal cell carcinoma. **Proc Am Assoc Cancer Res** 1992;33:1857.
3. Peoples GE, Davey MP, Schoof DD, Eberlein TJ. Selective usage of TCR V β genes in ovarian-specific CTL. **Proc Am Assoc Cancer Res** 1993;34:488.
4. Yoshino I, Schoof DD, Peoples GE, Eberlein TJ. The sensitivity of ovarian epithelial tumor cells to cytotoxic T cells is associated with the expression of HER2/neu. **Surg Forum** 1993;492-5.
5. Peoples GE, Davey MP, Schoof DD, Eberlein TJ. T cell receptor V β 2 and V β 6 mediate anti-tumor activity in ovarian tumor-infiltrating lymphocytes. **Surg Forum** 1993;44529-531.
6. Linehan DC, Peoples GE, Goedegebuure PS, Lee KY, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytokine release in ovarian tumor-infiltrating lymphocytes. **Proc Am Assoc Cancer Res** 1994;35:494.

7. Yoshino I, Goedegebuure PS, Peoples GE, Eberlein TJ. Activation of tumor-infiltrating lymphocytes by heat-stressed B cells. **Proc Am Assoc Cancer Res** 1994;35:479.
8. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export vascular growth factors related to heparin-binding EGF-like growth factor (HB-EGF) and basic fibroblast growth factor (bFGF): Differential release by CD4⁺ and CD8⁺ T cells. **Proc Am Assoc Cancer Res** 1994;35:184.
9. Peoples GE, Smith RC, Linehan DC, Goedegebuure PS, Eberlein TJ. Ovarian and breast cancer express shared antigenic peptides recognized by tumor-specific CTL. **Surg Forum** 1994;45:565.
10. Linehan DC, Peoples GE, Parikh AS, Goedegebuure PS, Eberlein TJ. Ovarian and breast tumor-associated T-lymphocytes stimulated with an antigenic peptide derived from HER2/neu show enhanced cytotoxicity against autologous tumor. **Surg Forum** 1994;45:568.
11. Linehan DC, Goedegebuure PS, Peoples GE, Eberlein TJ. T-cells isolated from breast cancer patients recognize a HER2/neu-derived tumor-associated antigen (TAA) shared by several epithelial-based tumors. **Surg Forum** 1995;46:496-8.
12. Peoples GE, Blotnick S, Freeman MR, Eberlein TJ. Tumor-infiltrating lymphocytes produce potent vascular growth factors in the tumor environment. **Proc Am Assoc Cancer Res** 1996;37:43.
13. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Curley SA, Skibber JM. Cost-effectiveness and outcomes of therapy for recurrent rectal cancer. **Surg Forum** 1997;48:621-3.
14. Kim DK, Lee T, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Wharton JT, Kim JW, Ioannides CG. Folate binding protein peptides presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. **Proc Am Assoc Cancer Res** 1999;40:657.
15. Peoples GE, Whiteman SK, Ryan G, Lee TV, Ioannides CG. Lymphocytes from ovarian and breast cancer patients secrete the anti-angiogenic CXC chemokine IP-10 in response to tumor antigens. **Surg Forum** 2000;51:421-3.
16. Ioannides CG, Tuttle TM, Peoples GE, Honda T, Kim K-K, Kudelk AP, Murray JL, Gershenson DM. Epitope-specific T-cell immunity to breast cancer. **Proc Era of Hope, DoD Breast Cancer Research Program Meeting** 2000;2:647-8.
17. Ryan GB, Fisk BA, Ioannides CG, Sesterhenn IA, Moul JW, McLeod DG, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine in prostate cancer. **Proc Am Assoc Cancer Res** 2001;42:681.
18. Swan EA, Custer JL, Lee TV, Kuerer HM, Peoples GE, Gershenson DM, Ioannides CG. Helper effects for HER-2 specific CTL induction by a HER-2 peptide. **FASEB J** 2001.
19. Ryan GB, Fisher CM, Srivastava S, McLeod DG, Moul J, Peoples GE. A comparison of the immunogenicity of HER2/neu peptide (E75) and PSA peptides for the optimal vaccine strategy in prostate cancer. **Surg Forum** 2001;52:420-2.

20. Woll MM, Fisher CM, Ryan GB, Ponniah S, Peoples GE. Evaluation of HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine (E75) in prostate and breast cancer patients. **Proc Am Assoc Cancer Res** 2002;43:142.
21. Fisher CM, Woll MM, Ryan GB, Peoples GE, Ponniah S. Optimal detection of HER2/neu (E75) specific CD8 T cells using the HLA-A2:Ig dimer. **Proc Am Assoc Cancer Res** 2002;43:975.
22. Gurney JM, Woll MM, Storrer CE, Fisher CM, Shriver CD, Ponniah S, Peoples GE. In vivo peptide specific CD8+ clonal expansion and epitope spreading in breast cancer patients receiving a HER2/neu peptide vaccine. **Proc Am Assoc Cancer Res** 2003;44:396-7.
23. Gurney JM, Woll MM, Storrer CE, Fisher CM, Shriver CD, Ponniah S, Peoples GE. In vivo monitoring of the immune response in breast cancer patients receiving a HER2/neu peptide vaccine. **J Am Coll Surg** 2003;197:S81-82.
24. Hueman MT, Gurney JM, Storrer CE, Kotula L, Jackson KA, Wilson M, McLeod DG, Moul JW, Shriver CD, Ponniah S, Peoples GE. Immunological studies of vaccine-specific immune responses in breast and prostate cancer patients receiving a HER2/neu (E75) vaccine. **J Immunother** 2003;26:S8.
25. Hueman MT, Gurney JM, Storrer CE, Kotula L, Jackson K, Wilson M, Shriver CD, Ponniah S, Peoples GE. Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine. **Ann Surg Oncol** 2004;11:S69 (#66).
26. Hueman MT, Gurney JM, Woll MM, Storrer CE, Kotula L, Wilson M, Jackson KA, Shriver CD, Ponniah S, Peoples GE. Clinical trial results of node positive breast cancer patients receiving a HER2/neu (E75) vaccine. **Proc Am Assoc Cancer Res** 2004;45:325 (#1416).
27. Hueman MT, Gurney JM, Woll MM, Storrer CE, Kotula L, Jackson KA, Wilson M, McLeod DG, Moul JW, Ponniah S, Peoples GE. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high risk prostate cancer patients. **Proc Am Assoc Cancer Res** 2004;45:163 (#705).
28. Hueman MT, Gurney JM, Woll MM, Storrer CE, McLeod DG, Shriver CD, Ponniah S, Peoples GE. A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients. **J Am Coll Surg** 2004;199:S92.
29. Mittendorf ME, Hueman MT, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the Cd107a cytotoxicity assay for the detection of cytolytic CD8 cells recognizing HER2/neu vaccine peptides. **J Surg Res** 2004;121:327 (#P65).
30. Storrer CS, Hueman MT, Gurney JM, McLeod DG, Moul JW, Shriver CD, Peoples GE, Ponniah S. Comparison of HLA-A2 dimer and tetramer molecules for the immunological monitoring of breast and prostate cancer vaccine clinical trials. **Clin Invest Med** 2004;27:211D (#53.315).

31. Moroni M, Pedraza L, Storrer CE, Foley RJ, Shriver CD, Ponniah S, Peoples GE. Assessing the humoral immune response in breast cancer patients receiving a single cytotoxic T lymphocyte epitope HER2/*neu* peptide vaccine. **Br Cancer Res Treat** 2004;88:S182 (#4100).
32. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. The impact of a polymorphism in the HER2 protein on a peptide vaccination strategy. **Br Cancer Res Treat** 2004;88:S247 (#6080).
33. Mittendorf EA, Storrer CE, Hueman MT, Shriver CD, Peoples GE, Ponniah S. Evaluation of the CD107a cytotoxicity assay for the detection of the cytolytic CD8 T cells recognizing HER2/*neu* vaccine peptides. **Br Cancer Res Treat** 2004;88:S245 (#6073).
34. Dehqanzada ZA, Storrer CE, Hueman MT, Foley R, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/*neu* vaccine using Luminex® technology. **Ann Surg Oncol** 2005;12:S47 (#P20).
35. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigation of a combination of trastuzumab and HER2 peptide vaccines for the treatment of breast cancer. **Ann Surg Oncol** 2005;12:S34 (#87).
36. Hueman MT, Stojadinovic A, Gurney JM, Dehqanzada ZA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Levels of circulating regulatory CD4⁺CD25⁺ T cells decreased in breast cancer patients after vaccination with a HER2/*neu* (E75) peptide. **Ann Surg Oncol** 2005;12:S52 (#P35).
37. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Foley RJ, Jama Y, Harris KA, Shriver CD, Peoples GE, Ponniah S. Reduction of regulatory T cell levels and enhanced anti-tumor immune responses in breast cancer patients receiving a HER2 peptide (E75) vaccine. **Proc Am Assoc Cancer Res** 2005;46:247 (#3451).
38. Dehqanzada ZA, Storrer CE, Hueman MT, Foley R, Harris KA, Jama Y, Shriver CD, Ponniah S, Peoples GE. Serum cytokine levels in breast cancer patients before and after receiving a HER2/*neu* vaccine assessed using multiplex technology. **Proc Am Assoc Cancer Res** 2005;46:247 (#3452).
39. Mittendorf EA, Storrer CE, Dehqanzada ZA, Hueman MT, Foley RJ, Jama Y, Harris KA, Shriver CD, Peoples GE, Ponniah S. Induction of CD8 T lymphocytes specific for the recognition of a breast cancer-associated polymorphism in the HER2/*neu* protein in a clinical trial with the HER2 E75 peptide vaccine. **Proc Am Assoc Cancer Res** 2005;46:247 (#3449).
40. Moroni M, Pedraza L, Storrer CE, Foley RJ, Shriver CD, Ponniah S, Peoples GE. Immunoprofiling the cancer-specific humoral immune response in sera from node-positive and node-negative breast cancer patients. **Proc Am Assoc Cancer Res** 2005;46:143 (#1541).
41. Proctor C, Ponniah S, Peoples GE, Shriver CD, Mueller SC, Moroni M. Inverse relationship between Syk and HER2/*neu* in breast epithelial cancer cell lines. **Proc Am Assoc Cancer Res** 2005;46:142 (#1514).
42. Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S, Peoples GE. Clinical trial results of a HER2/*neu* (E75) vaccine to prevent recurrence

- in high risk breast cancer patients. **J Clin Oncol 2005 ASCO Annual Meeting Proceedings** 2005;23:184s (#2575).
43. Dehqanzada Z, Hueman MT, Shriver CD, Ponniah S, Peoples GE. Prognostic significance of HLA-A2 status in breast cancer patients. **J Clin Oncol 2005 ASCO Annual Meeting Proceedings** 2005;23:886s (#9702).
 44. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, and Peoples GE. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. **J Am Coll Surg** 2005;201(3):S79.
 45. Dehqanzada ZA, Storrer CE, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Correlation of serum MCP-1 levels with clinical prognostic variables and endogenous and induced anti-tumor immunity in breast cancer patients. **J Am Coll Surg** 2005;201(3):S86.
 46. Dehqanzada ZA, Storrer CE, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Elevated serum MCP-1 level is associated with favorable clinical prognostic factors and immune response and can be induced by a HER2/*neu* (E75) vaccine in breast cancer patients. **Br Cancer Res Treat** 2005;94:S58 (#1057).
 47. Mittendorf EA, Khoo S, Dehqanzada ZA, Hueman MT, Storrer CE, Harris KA, Shriver CD, Ponniah S, Peoples GE. Phase Ib trial of the HER2/*neu* peptide (E75) vaccine for optimal dosing in node-negative breast cancer patients. **J Surg Res** 2006;130:216.
 48. Khoo S, Storrer CE, Harris KA, Jama YH, Dehqanzada ZA, Shriver CD, von Hofe E, Ponniah S, Peoples GE. Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/*neu* MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients. **J Surg Res** 2006;130:217.
 49. Khoo S, Banez LL, Dehqanzada ZA, Storrer CE, Srivastava S, Ponniah S, Peoples GE. Comparison of serum cytokine levels in breast and prostate malignancies. **J Surg Res** 2006;130:246.
 50. Hamsher C, Smith A, Dehqanzada ZA, Khoo S, Shriver CD, Ponniah S, Peoples GE, Moroni M. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients. **Ann Surg Oncol** 2006;13:P108.
 51. Mittendorf EA, Storrer CE, Flora MN, Shriver CD, Peoples GE, Ponniah S. The development of a novel method to identify immunogenic peptides for use in cancer vaccines. **Ann Surg Oncol** 2006;13:P101.
 52. Stojadinovic A, Hamsher C, Shriver CD, Hooke J, Kovatich A, Ponniah S, Peoples GE, Moroni M. Correlation of ORP150 with hormone receptor and nodal status in invasive breast cancer. **Proc Am Assoc Cancer Res** 2006;47:1954.
 53. Hamsher C, Shriver CD, Ponniah S, Peoples GE, Moroni M. Serum-induced matrigel outgrowth of MDA-MB-231 can differentiate between node-negative and node-positive breast cancer patients. **Proc Am Assoc Cancer Res** 2006;47:5160.

54. Khoo S, Storrer CE, Harris KA, Jama YH, Smith AM, Shriver CD, Peoples GE, Ponniah S. Development of a modified ELISPOT assay for the immunological monitoring of *in vivo* and *in vitro* immune responses to a HER2/*neu* MHC class II peptide vaccine for cancer immunotherapy. **Proc Am Assoc Cancer Res** 2006;47:1979.
55. Dehqanzada ZA, Storrer CE, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE. Luminex analysis of serum IL-6, eotaxin and MCP-1 levels can predict stage of disease in breast cancer patients. **Proc Am Assoc Cancer Res** 2006;47:3595.
56. Khoo S, Kao TC, Dehqanzada ZA, Storrer CE, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Developing a predictive model for disease status in breast cancer patients using Th1 and Th2 serum cytokine profiles. **J Clin Oncol 2006 ASCO Annual Meeting Proceedings** 2006; 24:560S.
57. Khoo S, Storrer CE, Harris KA, Jama YH, Dehqanzada ZA, Murray JL, Shriver CD, von Hofe E, Ponniah S, Peoples GE. Early results of a phase I clinical trial of an Ii-Key/HER2/*neu* MHC class II peptide-based vaccine in breast cancer patients. **J Clin Oncol 2006 ASCO Annual Meeting Proceedings** 2006;24:108S.
58. Hueman MT, Khoo S, Storrer CE, Harris KA, Jama YH, Shriver CD, Ponniah S, and Peoples GE. Immunological monitoring of regulatory T cells by flow cytometry in a novel HLA Class-II HER2/*neu* peptide vaccine clinical trial in breast cancer patients. **J Am Coll Surg** 2006;203:S79.
59. Khoo S, Storrer CE, Harris KA, Jama YH, Dehqanzada ZA, Murray JL, Shriver CD, von Hofe E, Ponniah S, and Peoples GE. Early results of a phase I clinical trial of an Ii-Key/Her2/*neu* MHC class II peptide-based vaccine in breast cancer patients. **J Am Coll Surg** 2006;203:S81-82.
60. Mittendorf EA, Storrer CE, Flora MN, Shriver CD, Peoples GE, Ponniah S. The development of a novel method to identify immunogenic peptides for use in cancer vaccines. **J Am Coll Surg** 2006;203:S79.
61. Peoples GE, Khoo S, Dehqanzada ZA, Mittendorf EA, Hueman MT, Gurney JM, Woll MM, Ryan GB, Storrer CE, Harris KA, Jama YH, Smith AM, Shriver CD, Ioannides CG, Ponniah S. Combined clinical trial results of a HER2/*neu* (E75) vaccine for prevention of recurrence in high-risk breast cancer patients. **Br Cancer Res Treat** 2006;100:4.
62. Khoo S, Storrer CE, Harris KA, Jama YH, Dehqanzada ZA, Mittendorf EA, Murray JL, Shriver CD, von Hofe E, Ponniah S, Peoples GE. Results of a phase I clinical trial of an Ii-Key/HER2/*neu* MHC class II peptide-based vaccine in breast cancer patients. **Br Cancer Res Treat** 2006;100:1122.
63. Hueman MT, Holmes JP, Storrer CE, Jama YH, Smith AM, Khoo S, Stojadinovic A, Ponniah S, and Peoples GE. Immune monitoring of CD4+CD25+FoxP3+ regulatory T cells in a novel HLA Class-II HER2/*neu* peptide vaccine clinical trial in breast cancer patients. **Ann Surg Oncol** 2007;S14:91.
64. Stojadinovic A, Hueman MT, Holmes JP, Mittendorf EA, Ponniah S, and Peoples GE. Quantification and phenotypic characterization of circulating tumor cells (CTCs) for monitoring

- response to preventative vaccine-based immunotherapy for breast cancer. **Ann Surg Oncol** 2007;S14:26.
65. Amin A, Holmes JP, Hueman MT, Khoo S, Storrer CE, Smith AM, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Assessment of pathologic and immunologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide vaccine. **Proc Am Assoc Cancer Res** 2007;48:#1859.
 66. Holmes JP, Amin A, Hueman MT, Khoo S, Storrer CE, Jama YH, Smith AM, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Breast cancer patients have different levels of endogenous CD8 T cells capable of recognizing a HER2/*neu* peptide (E75) used as a cancer vaccine in clinical trials. **Proc Am Assoc Cancer Res** 2007;48:#1860.
 67. Hueman MT, Holmes JP, Storrer CE, Jama YH, Smith AM, Khoo S, Stojadinovic A, Ponniah A, Peoples GE. Comparing CD4⁺CD25⁺FoxP3⁺ regulatory T cell levels with ex vivo immune assays and clinical delayed type hypersensitivity responses in a novel HLA Class II HER2/*neu* peptide vaccine clinical trial in breast cancer patients. **Proc Am Assoc Cancer Res** 2007;48:#1861.
 68. Amin A, Stojadinovic A, Holmes JP, Storrer CE, Smith AM, Jama YH, Craig D, Ponniah S, Peoples GE. Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with a preventive HER2/*neu* E75-peptide vaccine. **J Clin Oncol** 2007;25:#3059.
 69. Holmes JP, Amin A, Storrer CE, Smith AM, Jama YH, McNeil A, Craig D, Ponniah S, Peoples GE. Clinical and immunologic effects of a HER2/*neu* (E75) peptide vaccine booster in previously vaccinated breast cancer patients. **J Clin Oncol** 2007;25:#3014.
 70. Holmes JP, Patil R, Amin A, Jama Y, McNeil A, Hueman M, Craig D, Ponniah S, Peoples GE. Optimal dose and schedule of a HER2/*neu* peptide (E75) vaccine in disease-free breast cancer patients: Results from two phase I/II clinical trials. **Br Cancer Res Treat** 2007; 21:#301
 71. Carmichael M, Holmes JP, Mittendorf EA, Amin A, Hueman MT, Ponniah S, Peoples GE. Clinical results of a phase I trial of a HER2/*neu*-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients. **Br Cancer Res Treat** 2007; 21:#302.
 72. Patil R, Holmes JP, Amin A, Carmichael M, Jama Y, McNeil A, Hueman MT, Craig D, Ponniah S, Peoples GE. Clinical and immunologic responses of HLA-A3⁺ breast cancer patients vaccinated with the HER2/*neu*-derived peptide vaccine, E75, in a phase I clinical trial. **Br Cancer Res Treat** 2007;19:#2116.
 73. Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Intra-antigenic epitope spreading in HLA-A2⁺ breast cancer patients vaccinated with a MHC class I peptide (GP2) derived from the transmembrane region of HER2/*neu*. **J Immunother** 2007;30:#896.
 74. Hird LC, Gates JD, Carmichael M, Holmes J, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Impact of Trastuzumab Treatment on HER2/*neu* Peptide Vaccination-Preliminary Results for a Combination Immunotherapy. **J Surg Res** 2008; 44:#180-1.

75. Gates JD, Hird LC, Shriver CD, Peoples GE, Stojadinovic A. Should thyroid ultrasound be performed on all patients undergoing minimally invasive parathyroid surgery (MIPS)? **J Surg Res** 2008;44:#280.
76. Benavides LC, Amin A, Holmes JP, Gates JD, Hueman MT, Carmichael MG, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Pathologic and immunologic patterns among breast cancer (BCa) patients with clinical recurrence after vaccination with a preventive HER2/*neu* peptide vaccine (E75). **Ann Surg Oncol** 2008; P143.
77. Gates JD, Hird LC, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Intra-antigenic epitope spreading in HLA-A2⁺ BrCa patients vaccinated with a MHC Class I peptide (GP2) derived from the transmembrane region of HER2/*neu*. **Ann Surg Oncol** 2008;P142.
78. Benavides LC, Gates JD, Carmichael MG, Holmes JP, Hueman MT, Mittendorf EA, Patel R, Stojadinovic A, Craig D, Ponniah S, Peoples GE. Response to a preventive HER2/*neu* peptide (E75) vaccine based on HER2/*neu* status. **Proc Am Assoc Cancer Res** 2008;49:#2545.
79. Carmichael MG, Benavides LC, Gates JD, Patil R, Amin A, Storrer CE, Jama YH, Barrow LC, Mursal M, Craig D, Ponniah S, Peoples GE, Holmes JP. Clinical and immunologic effects of a HER2/*neu* (E75) peptide vaccine booster series in previously vaccinated breast cancer patients. **Proc Am Assoc Cancer Res** 2008;49:#2832.
80. Gates JD, Stojadinovic A, Benavides LC, Carmichael MG, Hueman MT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Assessment of circulating tumor cells (CTCs) for monitoring immediate and long-term response to primary and booster inoculations with a preventive HER2/*neu* vaccine in breast cancer patients. **Proc Am Assoc Cancer Res** 2008;49:#2833.
81. Enewold L, Zhu K, Stojadinovic A, Peoples GE, Devesa SS. Trends in thyroid cancer incidence by race and ethnicity in the United States. **Am J Epidemiol** 2008;167 (Suppl):S62.
82. Benavides LC, Gates JD, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Optimal method of dosing HER2/*neu* peptide vaccines: from U.S. Military Cancer Institute Clinical Trials Group Study I-01, I-02, I-03, and I-04. **Br Cancer Res Treat** 2008:#3139.
83. Gates JD, Benavides LC, Carmichael MG, Hueman MT, Holmes JP, Khoo S, Stojadinovic A, von Hofe E, Ponniah S, Peoples GE. Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/*neu* peptide (AE37). **Br Cancer Res Treat** 2008:#3134.
84. Holmes JP, Benavides LC, Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Increased incidence of hormone-receptor negative and basal type breast cancer tumors among HLA-A2⁺ patients and possible implications for cancer vaccine trials: US Military Cancer Institute Clinical Trials Group Study I-01, I-02, I-03, and I-04. **Br Cancer Res Treat** 2008:#3153.
85. Clifton GT, Benavides L, Gates J, McCall S, Rivera S, Holmes J, Mittendorf E, Merrill G, Ponniah S, Peoples GE. Monitoring cytokine levels to adjust dosing and predict response to HER2/*neu* peptide-based cancer vaccines. **J Surg Res** 2009;151:289.

86. Zhou J, Enewold L, Peoples GE, Clifton GT, Potter JF, Stojadinovic A, Zhu K. Cancer screening among Hispanic and White Non-Hispanic women, 2000-2005. **Am Public Health Assoc** Nov 2009.
87. Clifton, GT, Holmes JP, Patel R, Benavides LC, Gates JD, Heuman MT, Mittendorf EA, Ponniah S, Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine. **Ann Surg Oncol** 2009 ;16(SI):#P92.
88. Clifton GT, Patil R, Holmes JP, Benavides LC, Gates JD, Jama Y, Mursal, Zacharia A, Ciano K, Mittendorf EA, Ponniah S, Peoples GE. The HLA-A2 restricted HER2/neu derived peptides (E75 and GP2) are both highly immunogenic in HLA-A3 breast cancer patients vaccinated with an E75 vaccine. **Proc Am Assoc Cancer Res** 2009;#720.
89. Clifton GT, Holmes JP, Benavides LC, Gates JD, McCall S, Rivera S, Mittendorf EA, Stojadinovic A, Merrill G, Ponniah S, Peoples GE. Assessment of circulating tumor cells in disease-free breast cancer patients vaccinated with HER2/neu peptide vaccines or immunoadjuvant GM-CSF. **Proc Am Assoc Cancer Res** 2009;#3610.
90. Clifton GT, Ciano K, Zacharia A, Mursal M, Jama Y, Ishizaka S, Hawkins L, Peoples GE, Ponniah S. E6020, a novel immunoadjuvant, is effective at stimulating HER2/neu cancer antigen-specific immunity in healthy donors and breast cancer patients. **J Immunother** 2009;32(9):#968.
91. Clifton GT, Holmes JP, Perez SA, Lorentz D, Georgakopoulou K, Benavides LC, Gates J, Mittendorf EA, Ardavanis A, Gritzapis AD, Ponniah S, Papamichail M, Peoples GE. Interim analysis of a randomized phase II study of the novel HER2/neu peptide (GP2) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05. **Br Cancer Res Treat** 2009 #5110.
92. Peoples GE, Perez SA, Clifton GT, Holmes JP, Georgakopoulou K, Benavides LC, Gates JD, von Hofe E, Baxeavanis C, Mittendorf EA, Ardavanis A, Ponniah S, Papamichail M. Interim analysis of a randomized phase II study of the novel li-key hybrid HER2/neu peptide (AE37) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05. **Br Cancer Res Treat** 2009;#3183.
93. Clive KS, Tyler JA, Benavides LC, Sutcliffe JB, Ferrise LJ, Kirkpatrick AD, Banks KP, Bell LM, Saenger JS, Swiecki CW, Peoples GE. The impact of routine pretreatment magnetic resonance imaging on the surgical planning and outcome in newly diagnosed breast cancer patients. **J Surg Res** 2010;#26.6.
94. Clive KS, Tyler JA, Barchie MF, Sutcliff JB, Kirkpatrick AD, Banks KP, Bell LM, Saenger JS, Peoples GE. Are increased mastectomy rates based on pretreatment MRI findings justified? **Ann Surg Oncol** 2010;17:P49.

95. Patil R, Clifton GT, Clive K, Tyler J, Zacharia A, Jama Y, Mursal M, Ciano K, Holmes JP, Mittendorf EA, Peoples GE, Ponniah S. A modified HER2/neu peptide vaccine (2L9V-GP2) demonstrates enhanced CD8+ T cell recognition and stimulation in breast cancer patients at high risk for recurrence. **Proc Am Assoc Cancer Res** 2010;#LB-322.
96. Clifton GT, Patil R, Clive K, Tyler J, Zacharia A, Jama Y, Mursal M, Ciano K, Holmes JP, Mittendorf EA, Peoples GE, Ponniah S. Defining Regulatory T-cells as CD4+CD25hiCD127- or as CD4+CD25hiFoxP3+ in immune monitoring of cancer vaccine clinical trials. **Proc Am Assoc Cancer Res** 2010;#LB-329.
97. Clifton GT, Clive K, Patil R, Holmes J, Benavides LC, Gates JD, Tyler J, Mittendorf EA, Ponniah S, Peoples GE. Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations. **J Clin Oncol** 2010;28:#2565.
98. Clive KS, Summers T, Clifton GT, Patil R, Tyler J, Holmes JP, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/*neu*-based peptide vaccines. **J Clin Oncol** 2010;28:#2542.
99. Patil R, Clifton GT, Ciano K, Zacharia A, Mursal M, Jama Y, Krivak TC, Maxwell GL, Peoples G, Ponniah S. Evaluation of HER2/neu and folate binding protein (FBP) peptides in immunotherapy for endometrial cancer. **J Immunother** 2010;33:906.
100. Clifton GT, Clive K, Holmes J, Patil R, Benavides L, Gates J, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Cumulative findings from the E75 peptide vaccine adjuvant trials in breast cancer. **J Clin Oncol** 2010 (In Press).
101. Vreeland TJ, Clifton GT, Patil R, Clive KS, Sears AK, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Safety and clinical efficacy of multiple booster inoculations with the E75 adjuvant breast cancer vaccine. **Br Cancer Res Treat** 2010 #P2-20-01.
102. Olson MD, Clifton GT, Mittendorf EA, Peoples GE, Ponniah S, Holmes JP. Increased prevalence of HLA-DR3 among breast cancer patients: implications for Her2/neu peptide vaccine trials. **Br Cancer Res Treat** 2010 #P2-20-02.
103. Mittendorf EA, Perez S, Tzonis P, Clifton GT, Ardavanis A, Holmes JP, Lekka E, Baxevanis C, Ponniah S, Peoples GE, Papamichail M. Combination immunotherapy for breast cancer patients: safety and immunologic data from a phase II trials administering a HER2/neu-derived peptide vaccine (AE37+GM-CSF) sequentially or concurrently with trastuzumab in the adjuvant setting. **Br Cancer Res Treat** 2010 #P2-20-03.
104. Sears AK, Clifton GT, Perez SA, Clive K, Holmes JP, Georgakopoulou K, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Vaccine-specific immunologic responses to the novel II-

- Key hybrid HER-2/*neu* peptide (AE37) vaccine in a phase II clinical trial. **Ann Surg Oncol** 2011;18 (Suppl 1): P60.
105. Clifton GT, Sears AK, Perez SA, Clive KS, Holmes JP, Georgakopoulou K, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Vaccine-specific immunologic responses to the HER-2/*neu* peptide (GP2) vaccine in a prospective, randomized phase II clinical trial. **Ann Surg Oncol** 2011;18 (Suppl 1):P59.
 106. Sears AK, Clifton GT, Carmichael MG, Van Echo DC, Holmes JP, Zacharia A, Jama Y, Mursal M, Chiplis A, Mittendorf EA, Peoples GE, Ponniah S. Comparison of *in vitro* and *in vivo* immunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/*neu* peptide vaccines GP2 and AE37 in breast cancer patients. **Proc Am Assoc Cancer Res** 2011;LB-414/12.
 107. Sears AK, Clifton GT, Van Echo DC, Holmes JP, Zacharia A, Jama Y, Mursal M, Chiplis A, Mittendorf EA, Peoples GE, Ponniah S. Circulating regulatory T cells (CD4⁺CD25^{high}CD127^{low}) decrease in breast cancer patients after vaccination with a modified HER-2/*neu* HLA class II peptide (AE37) vaccine. **Proc Am Assoc Cancer Res** 2011;LB-413/11.
 108. Sears AK, Clifton GT, Patil R, Shumway NM, Carmichael MG, Van Echo DG, Holmes JP, Ponniah S, Mittendorf EA, Peoples GE. Sequential administration of trastuzumab and a CD8 T cell-eliciting HER-2/*neu* peptide vaccine in breast cancer patients compared to trastuzumab alone. *Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)*. Vol 29, No 15_suppl (May 20 Supplement), 2011:564.
 109. Clifton GT, Sears AK, Patil R, Shumway NM, Carmichael MG, Van Echo DG, Holmes JP, McCall S, Merrill GA, Ponniah S, Peoples GE, Mittendorf EA. Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER-2/*neu* peptide vaccine trial. *Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)*. Vol 29, No 15_suppl (May 20 Supplement), 2011:e11126.
 110. Sears AK, Clifton GT, Benavides LC, Gates JD, Holmes JP, Perez S, Ponniah S, Papamichail M, Peoples GE, Mittendorf EA. The relationship between immunologic response and recurrence in a phase II trial evaluating the HER-2/*neu* peptide vaccines AE37 and GP2 in breast cancer patients in the adjuvant settings. **J Am Coll Surg** Vol 213, Issue 3, Supplement, September 2011, Page S138.
 111. Sears AK, Clifton GT, Vreeland TJ, Hale DF, Holmes JP, Patil R, Ponniah S, Mittendorf EA, Peoples GE. Vaccination with the HER2-derived E75 peptide vaccine in breast cancer patients may confer greater benefit to patients with less aggressive disease. **J Immunother** 2011;34(9), November-December 2011.
 112. Hale DF, Perez SA, Sears AK, Clifton GT, Vreeland TJ, Holmes JP, Ardavanis A, Pistamaltzian N, Rellias G, Ponniah S, Papamichail M, Peoples GE, Mittendorf EA. An update of a phase II

- trial of the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. **Cancer Res** 2011 #P1-13-01.
113. Vreeland TJ, Clifton GT, Sears AK, Hale DF, Patil R, Clive KS, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Long-term clinical benefit of adjuvant breast cancer vaccine: 5 year efficacy of E75 with multiple booster inoculations. **Cancer Res** 2011 #P1-13-02.
 114. Sears AK, Clifton GT, Vreeland TJ, Hale DF, Ponniah S, Mittendorf EA, Peoples GE. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence. **Cancer Res** 2011 #OT3-01-18.
 115. Nissan A, Protic M, Bilchik A, Howard R, Peoples GE, Stojadinovic A. Targeted nodal assessment improves survival in early colon cancer: prospective randomized USMCI Clinical Trials Group GI-01, Final Results. **Ann Surg** 2012 (In Press).
 116. Vreeland TJ, Hale DF, Clifton GT, Sears AK, Perez SA, Ardavanis A, Pistamaltzian N, Rellias G, Ponniah S, Papamichail M, Peoples GE, Mittendorf EA. Booster inoculations safely sustain the immune effects of a CD4-targeted peptide cancer vaccine. **Ann Surg Oncol** 2012;19:#P98.
 117. Hale DF, Vreeland TJ, Dabney RS, Clifton GT, Sears AK, Pappou E, Anastasopoulou E, Ardavanis A, Ponniah S, Papamichail M, Perez S, Shumway N, Peoples GE, Mittendorf EA. Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine. **Proc Am Assoc Cancer Res** 2012 #LB-218/3.
 118. Vreeland TJ, Dabney RS, Hale DF, Sears AK, Clifton GT, Zacharia A, Jama Y, Chiplis A, Mursal M, Shumway NM, Patil R, Holmes JP, Peoples GE, Ponniah S, Mittendorf EA. Immune reconstitution after chemotherapy correlates with increased *in vitro* immune response in breast cancer patients undergoing peptide vaccine therapy. **Proc Am Assoc Cancer Res** 2012 #LB-130/6.
 119. Dabney RS, Hale DF, Vreeland TJ, Clifton GT, Sears AK, Patil R, Ponniah S, Shumway NM, Peoples GE, Mittendorf EA. Safety and long-term efficacy of booster inoculations with the E75 peptide vaccine in HER2/*neu*-expressing breast cancer patients. *Journal of Clinical Oncology*, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20 Supplement), 2012: 2529
 120. Hale DF, Perez SA, Vreeland TJ, Trappey AF, Dabney RS, Berry JS, Ardavanis A, Sears AK, Papamichail M, Clifton GT, Pappou E, Patil R, Anastasopoulou E, Ponniah S, Shumway NM, Peoples GE, Mittendorf EA. An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial. *Journal of Clinical Oncology*, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20 Supplement), 2012: 625

121. Vreeland TJ, Hale DF, Sears AK, Clifton GT, Pappou E, Dabney RS, Ardavanis A, Patil R, Ponniah S, Anastasopoulou E, Perez SA, Papamichail M, Shumway NM, Peoples GE, Mittendorf EA. From bench to bedside: the use of the Ii-Key technology to improve helper peptides for clinical use in cancer vaccines. *Journal of Clinical Oncology*, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20 Supplement), 2012: 2508
122. Mittendorf EA, Perez SA, Hale DF, Vreeland TJ, Sears AK, Clifton GT, Ardavanis A, Shumway NM, Murray JL, Ponniah S, Papamichail M, Peoples GE. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. **J Clin Oncol** 30, 2012 (Suppl 27; abstr 109).
123. Hale DF, Perez S, Vreeland TJ, Dabney R, Papamichail M, Clifton GT, Sears A, Ponniah S, Peoples GE, Mittendorf EA. Assessment of disease features and immune response in breast cancer patients with recurrence after receiving AE37, a HER2 peptide vaccine. **J Am Coll Surg** 2012 (In Press).
124. Radowsky J, Eberhardt JS, Peoples GE, Burch H, Stojadinovic A. Bayesian modeling of a thyroid cancer tumor registry to predict outcomes of papillary thyroid cancer (PTC). **Thyroid** 2012 (In Press).
125. Vreeland TJ, Clifton GT, Hale DF, Sears AK, Patil R, Holmes JP, Ponniah S, Mittendorf EA, Peoples GE. Final results of the phase I/II trials of the E75 adjuvant breast cancer vaccine. **Cancer Res** 2012;72(24 Suppl.) #P5-16-02.
126. Hale DF, Vreeland TJ, Perez SA, Berry JS, Ardavanis A, Trappey AF, Tzonis P, Sears AK, Clifton GT, Shumway NM, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients. **Cancer Res** 2012;72(24 Suppl.) #P5-16-05.
127. Trappey AF, Vreeland T, Clifton G, Sears A, Clive K, Ferrise S, Saenger JS, Kirkpatrick AD, Lallemand M, Peoples GE. Pure flat epithelial atypia (PFEA): Excise or observe. **Ann Surg Oncol** 2013; 20 (Suppl 1):S4, P25.
128. Berry J, Vreeland T, Hale D, Sears A, Dabney RS, Ponniah S, Perez SA, Clifton GT, Hintz C, Covelli JD, Papamichail M, Peoples GE, Mittendorf EA. Factors associated with recurrence in breast cancer patients vaccinated with the HER2-derived GP2 vaccine. **Ann Surg Oncol** 2013;20 (Suppl 1):S59, P66.
129. Vreeland TJ, Berry JS, Trappey AF, Hale D, Clifton GT, Sears A, Shumway NM, Holmes JP, Ponniah S, Mittendorf EA, Ioannides CG, Peoples GE. Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor- α (FR α). **Ann Surg Oncol** 2013;20 (Suppl 1):S59, P67.

130. Berry JS, Trappey AF, Vreeland TJ, Hale DF, Clifton GT, Sears AK, Shumway NM, Ponniah S, Holmes JP, Ioannides C, Mittendorf EA, Peoples GE. Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor-alpha. **Cancer Res** 2013;73:1251.
131. Trappey AF, Berry JS, Vreeland TJ, Hale DF, Sears AK, Clifton G, Ponniah S, Papamichail M, Perez SA, Mittendorf E, Peoples GE. Delayed urticarial reactions in the phase II trial of HER2/neu peptide vaccines + GM-CSF vs. GM-CSF alone in high risk breast cancer patients. **Cancer Res** 2013;73:4670.
132. Patil R, Clifton GT, Litton JK, Shumway NM, Vreeland TJ, Berry JS, Trappey AF, Ponniah S, Peoples GE, Mittendorf EA. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting. **J Clin Oncol** 31(15)(May 20 Suppl);2013:3096.
133. Trappey AF, Berry JS, Vreeland TJ, Hale DF, Sears AK, Ponniah S, Perez SA, Clifton GT, Papamichail M, Shumway NM, Mittendorf EA, Peoples GE. Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence. **J Clin Oncol** 31(15)(May 20 Suppl);2013:3097.
134. Trappey F, Berry JS, Vreeland TJ, Hale DF, Sears AK, Ponniah S, Perez SA, Clifton GT, Papamichail M, Peoples GE, Mittendorf EA. Randomized phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: A planned interim analysis. **J Clin Oncol** 31(15)(May 20 Suppl);2013: 3005.
135. Berry JS, Trappey AF, Sears AK, Vreeland TJ, Clifton GT, Hale DF, Patil R, Holmes JP, Ponniah S, Mittendorf EA, Peoples GE, Van Echo DC. Biomarker correlation to clinical response in phase I/II trials of the adjuvant breast cancer vaccine neuvax (nelipepimut-S or E75). **J Clin Oncol** 31(15)(May 20 Suppl);2013:TPS3126.
136. Trappey AF, Berry JS, Mursal M, Jama Y, Zacharia A, Pham R, Margulies E, Ponniah S, Mittendorf EA, Peoples GE. Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37). **J Am Coll Surg** 2013;217(3)(Supplement September 2013):S134.
137. Berry JS, Schneble EJ, Trappey AF, Vreeland TJ, Clifton GT, Hale DF, Sears AK, Ponniah S, Mittendorf EA, Peoples GE. Preliminary results for the phase I trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients. **J Immunother Cancer** 2013;1 (Suppl 1):P200.
138. Schneble EJ, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Sears AK, Clifton GT, Ponniah S, Shumway NM, Mittendorf EA, Peoples GE. Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients. **J Immunother Cancer** 2013;1 (Suppl 1):P236.

139. Trappey AF, Berry JS, Vreeland TJ, Guy CT, Diane HF, Alan SK, Erika SJ, Ferrise L, Shumway NM, Papamichail M, Perez SA, Ponniah S, Mittendorf EA, Peoples GE. HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials. **Cancer Res** 2013;73:P4-13-05.
140. Berry JS, Trappey AF, Vreeland TJ, Schneble EJ, Clifton GT, Hale DF, Sears AK, Ponniah S, Shumway NM, Mittendorf EA, Peoples GE. Preliminary results for the phase I trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients. **Cancer Res** 2013;73:P4-13-02.
141. Vreeland TJ, John BS, Trappey AF, Schneble EJ, Hale DF, Clifton GT, Shumway NM, Perez SA, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence. **Cancer Res** 2013;73:P2-14-01.
142. John S. Berry IV, Alfred F. Trappey, James K. Aden, Alan K. Sears, Timothy J. Vreeland, Diane F. Hale, Guy T. Clifton, Sathibalan Ponniah, Elizabeth A. Mittendorf, and George E. Peoples. Predicting Clinical Benefit after Completion of Treatment with the Adjuvant Breast Cancer (BCa) Vaccine, NeuVax (Neli pepimut-S or E75). **American College of Surgeons**. 2013 (In Press).
143. Trappey A, Berry JS, Schneble E, Aden J, Vreeland TJ, Hale DF, Sears A, Brown R, Perez S, Clifton GT, Papamichail M, Ponniah S, Mittendorf E, Peoples GE. Induced immunity correlates with and may predict clinical benefit in the phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients. **Ann Surg Oncol** 2014;21 (Suppl 1):S11, 16.
144. Schneble E, Berry JS, Trappey AF, Hale DF, Vreeland TJ, Sears A, Clifton GT, Ponniah S, Papamichail M, Perez S, Peoples GE, Mittendorf E. The clinical benefit and safety of boosting the HER2 peptide vaccine (GP2+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence. **Ann Surg Oncol** 2014;21 (Suppl 1):S45, P6.
145. Schneble EJ, Trappey AF, Berry JS, Vreeland TJ, Hale DF, Sears AK, Clifton GT, Ponniah S, Mittendorf EA, Peoples GE. Immunologic effects of a HER2 peptide (GP2) vaccine booster in previously vaccinated breast cancer patients. **Cancer Res** 2014 (In Press).
146. Schneble EJ, Trappey AF, Berry JS, Vreeland TJ, Hale DF, Sears AK, Clifton GT, Ponniah S, Mittendorf EA, Peoples GE. HLA-A2 and HER2 expression levels as clinical prognostic factors in breast cancer patients: Implications for peptide cancer vaccine trials. **Cancer Res** 2014 (In Press).
147. Schneble EJ, Perez S, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Sears AK, Clifton GT, von Hofe E, Ardavannis A, Shumway N, Ponniah S, Papamichail M, Peoples GE, Mittendorf EA. Comparison of recurrent and non-recurrent breast cancer patients undergoing AE37 peptide vaccine therapy. **J Clin Oncol** 2014 (In Press).

148. Schneble EJ, Byrd KA, Vreeland T, Berry JS, Trappey AF, Clifton GT, Ponniah S, Mittendorf EA, McGuire WP, Conrads TP, Darcy KM, Maxwell GL, Hamilton CA, Elkas JC, Peoples GE. Comparison of recurrent and non-recurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy. **J Clin Oncol** 2014 (In Press).
149. Mittendorf EA, Schneble EJ, Perez S, Symanowski JT, Patil R, Vreeland TJ, Berry JS, Trappey AF, Hale DF, Sears AK, Clifton GT, von Hofe E, Ardavannis A, Ponniah S, Shumway N, Papamichail M, Peoples GE. Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine vs GM-CSF alone administered in the adjuvant setting to high risk breast cancer patients. **J Clin Oncol** 2014 (In Press).
150. Scheble EJ, Berry JS, Trappey AF, Vreeland TJ, Clifton GT, von Hofe E, Ardavannis A, Shumway N, Ponniah S, Papamichail M, Perez S, Mittendorf EA, Peoples GE. Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF). **J Am Coll Surg** 2014 (In Press).
151. Schneble EJ, Berry JS, Trappey AF, Vreeland TJ, Clifton GT, Ponniah S, Perez SA, Papamichail M, Peoples GE, Mittendorf EA. The clinical benefit and safety of boosting the HER2-peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence. **J Am Coll Surg** 2014 (In Press).
152. Schneble EJ, Perez S, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Greene J, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA. Primary analysis of the prospective, randomized, single-blinded phase II trial of GP2+GM-CSF vaccine vs GM-CSF alone administered in the adjuvant setting to high risk breast cancer patients. *J Clin Oncol* 32, 2014 (suppl 26; abstr 134)
153. Greene JM, Schneble EJ, Berry JS, Trappey AF, Vreeland TJ, Clifton GT, McGuire WP, Maxwell GL, Ponniah S, and GE. Preliminary Results of the Phase IIa Trial of a Folate Binding Protein (FBP) Adjuvant Cancer Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence. SITC 2014 Poster: *Journal for ImmunoTherapy of Cancer* 2014, 2(Suppl 3):P74
154. Greene JM, Schneble EJ, Martin J, Flores M, Trappey AF, Berry JS, Vreeland TJ, Hale DF, Clifton GT, Papamichail M, Perez S, Peoples GE, Mittendorf EA, Ponniah S. Correlation of HER2/neu Antibody Response to Clinical Response in a Phase II Trial of the AE37+GM-CSF HER2 Peptide Vaccine. SITC 2014 Poster: *Journal for ImmunoTherapy of Cancer* 2014, 2(Suppl 3):P90
155. Beth A Mittendorf, Erika J Schneble, Nuhad K Ibrahim, Julia M Greene, John S Berry, Alfred F Trappey, Guy T Clifton, Jarrod P Holmes, Sathibalan Ponniah, George E Peoples. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence [abstract]. In: *Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res* 2015;75(9 Suppl):Abstract nr OT3-1-09 SABCS

156. Clifton GT, Stassen S, Arrington K, Ponniah S, Greene J, Schneble EA, Victor, Peoples GE, Mittendorf EA. Results of a phase Ib trial of combination immunotherapy with HER2–derived peptide vaccine GP2+GM-CSF and trastuzumab in breast cancer patients. (In Press)
157. Greene JM, Schneble EJ, Yu X, Wagner TE, Peoples GE. A Phase I/IIa Clinical Trial of an Autologous Tumor/Dendritic Cell Fusion (Dendritoma) Vaccine with Low Dose Interleukin-2 in Stage IV Melanoma. (In Press)
158. Greene, JM, Schneble EJ, Litton JK, Martin J, Trappey AF, Berry JS, Vreeland TJ, Hale DF, Clifton GT, Ardavannis A, Papamichail M, Perez S, Ponniah S, Mittendorf EA, Peoples GE. Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr CT209
159. Greene, JM, Schneble EJ, Berry IV JS, Trappey III AF, Vreeland TJ, Clifton GT, McGuire WP, Maxwell GL, Ponniah S, Peoples GE. Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence. *J Clin Oncol* 33, 2015 (suppl; abstr e14031)
160. Greene JM, Schneble EJ, Martin J, Flores M, Berry, Trappey AF, Vreeland TJ, Hale DF, Sears AK, Clifton GT, von Hofe E, Ardavannis A, Shumway N, Ponniah S, Papamichail M, Perez S, Symanowski JT, Peoples GE, Mittendorf EA. Final Pre-specified Analysis of the Phase II Trial of the AE37+GM-CSF Vaccine in High Risk Breast Cancer Patients to Prevent Recurrence. *J Clin Oncol* 33, 2015 (suppl; abstr 622)
161. Greene JM, Schneble EJ, Ferrise L, Perez S, Ponniah S, Trappey AF, Berry JS, Papamichael M, Mittendorf EA, Peoples GE. Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of GP2+GM-CSF HER2 peptide vaccine. (In Press)
162. Greene JM, Schneble EJ, Berry JS, Trappey AF, Vreeland TJ, Clifton GT, Elkas JC, Hamilton CA, Darcy K, Maxwell GL, and Peoples GE. Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence. (In Press)
163. Greene JM, Hale DF, Schneble EJ, Yu X, Nichol P, Yin S, Wagner TE, and Peoples GE. Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles + dendritic cells vaccine (TLPLDC) in patients with solid tumors. (In Press)
164. Hardin MO, Jackson DO, Hale DF, Greene JM, Schneble EJ, Martin J, Flores M, Berry JS, Trappey AF, Vreeland TJ, Clifton GT, Herbert GS, von Hofe E, Perez S, Shumway N, Papamichail M, Peoples GE, Mittendorf EA. Impact of Boosting in the Phase II Trial of the AE37+GM-CSF Vaccine in High Risk Breast Cancer Patients to Prevent Recurrence (In Press)

165. Vreeland TJ, Jackson DO, Hale DF, Greene JM, Schneble EJ, Martin J, Flores M, Berry JS, Trappey AF, Hardin MO, Clifton GT, Herbert GS, Perez S, Shumway N, Papamichail M, Peoples GE, Mittendorf EA. Efficacy of Booster Inoculations in a Phase II Trial of GP2, a HER2-Derived Peptide Vaccine, for the Prevention of Breast Cancer Recurrence (In Press)
166. Jackson DO, Perez S, Hale DF, Greene JM, Schneble EJ, Martin J, Flores M, Berry JS, Trappey AF, Vreeland TJ, Hardin MO, Clifton GT, Herbert GS, Shumway N, Papamichail M, Mittendorf EA, Peoples GE. Correlation between pre-existing immunity and clinical response in a phase II trial using HER2 based peptide vaccines to prevent breast cancer recurrence. (In Press)
167. Nikolaos F Pistamaltzian, Eleftheria A Anastasopoulou, Panagiotis Tzonis, Joanne Kalogeropoulou, Alexandros Ardavanis, Elizabeth A Mittendorf, George E Peoples, Constantin N Baxevanis, Michael Papamichail, Sonia A Perez: Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients **Annals of Oncology** 26 (Supplement 8) viii1-viii4 2015.
168. Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence. (In Press)
169. Jackson D, Greene JM, Hale D, Schneble EJ, Wagner T, Yu X, Peoples GE. Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients. **Journal for ImmunoTherapy of Cancer** 2015.
170. Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical development of the E75 vaccine in breast cancer. **Breast Care**, 11:116-121, 2016.

BOOK CHAPTERS

1. Eberlein TJ, Peoples GE, Yoshino I, Burger U, Lee K, Li H, Douville LM, Goedegebuure PS. CD3 activation of tumor-infiltrating lymphocytes. **Immunotherapy of Cancer with Sensitized T Lymphocytes**. Michigan: University of Michigan Press 1994, pp. 15-34.
2. Peoples GE, Miller AR. Biologic Therapy of Cancer. **The M. D. Anderson Surgical Oncology Handbook**. 2nd Ed. Philadelphia: Lippincott, Williams, and Wilkins, 1999, pp. 447-77.
3. Peoples GE, Miller AR, Eberlein TJ. Tumor immunology. **The Handbook for Europe**. Indianapolis, IN: John Wiley and Sons, 2000.
4. Peoples GE (contributor). **Emergency War Surgery, 3rd US Revision**. David Lounsbury, Ronald Bellamy, Eds. Borden Institute: Washington, DC, 2004.
5. Mittendorf EA, Czerniecki BJ, Peoples GE. Breast Cancer Vaccines. **Kuerer's Breast Surgical Oncology**. New York: McGraw-Hill Professional, 2009, Chapter 91.

6. Peoples GE. Damage Control in Abdominopelvic Trauma. **War Surgery in Afghanistan and Iraq: A Series of Cases 2003-2007**. Nessen SC, Lounsbury DE, and Hetz SP, Eds. Borden Institute: Washington, DC, 2008, pp 199-200.
7. Steele SR, Peoples GE. Damage Control in the War Wounded. In **Advances in Wound Care**, vol 1. 2010. <http://www.liebertonline.com/doi/pdf/10.1089/9781934854013.31>
8. Haney BR, Shumway NM, Peoples MD. Targeted therapies – other agents in clinical trials. **Advances in the Management of Triple Negative Breast Cancer**. Future Medicine, 2011, pp 82-92.
9. Clifton GT, Mittendorf EA, Peoples GE. Immune checkpoint blockade for overcoming cancer tolerance. **Cancer Immunology: Translational Medicine from Bench to Bedside**. Nima Rezaei, Ed. New York: Springer Publishing, 2013 (Vol 30, No 15_suppl (May 20 Supplement), 2012: 2508).
10. Schneble EJ, Clifton GT, Hale D, and Peoples GE. *Peptide-based Cancer Vaccine Strategies and Clinical Results*. Invited Chapter; *Accepted*. Publication in Progress.
11. Vreeland TJ, Herbert GS, Peoples GE. *Cancer Vaccines for Solid Tumors*. Invited Chapter, *Accepted*. Publication in Progress.
12. Hale, DF, Vreeland, TJ, Peoples, GE. *Arming the Immune System to Prevent Cancer Recurrence*. ASCO Education Book 2016. Publication in Progress.

MANUALS

1. Peoples GE, and Eberlein TJ. Surgical Oncology. **The Brigham Surgical Resident's Manual**, 1996.
2. Department of Defense Breast Cancer Prevention, Education, and Diagnosis Work Group. **Department of Defense Breast Cancer Treatment Guideline Consensus Panel Report**, 1998.

PATENTS

Principal Inventor	US Patent 8,133,691 Stable Quantitation and Detection of Immune Response Levels with Non-Zero Background Peptides	2012
Principal Inventor	US Provisional Patent Combination Therapy with AE37 Peptide and an Antibody That Binds to Her2/NEU Protein	2010
Principal Inventor	US Provisional Patent Mosaic Helper Cancer Antigens	2010
Principal Inventor	US Patent 7,547,759 B2 Induction of Tumor Immunity by Variants of Folate Binding Protein	2009
Principal Inventor	US Patent 7,547,759 B2 Induction of Tumor Immunity by Variants of Folate Binding Protein (Divisional – J65)	2009

Principal Inventor	Serial No. PCT/US2009/067264 Vaccine for the Prevention of Breast Cancer Recurrence	2009
Principal Inventor	Serial No. 12/602,214 Practical application (dosing and scheduling) and extensions of uses of the HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients	2008
Principal Inventor	US Provisional Patent Targeted Identification of Immunogenic Peptides	2008
Principal Inventor	US Provisional Patent Targeted Identification of Immunogenic Peptides (Divisional – GP2 + anti-HER2 mAb)	2008
Principal Inventor	Targeted Identification of Immunogenic Peptides (Divisional – E75 + anti-HER2 mAb)	2008
Principal Inventor	Serial No. 10/507,009 Controlled Modulation of Amino Acid Side Chain Length of Peptide Antigens (E75)	2003
Principal Inventor	US Provisional Patent Ii-Key/HER-2/neu Hybrid Cancer Vaccine	2007
Principal Inventor	US Provisional Patent Use of Peptide/HLA Coated Beads in Immunologic Assays	2005
Principal Inventor	US Provisional Patent Novel Method for Identification of Immunogenic Peptides for Use in Cancer Vaccines	2005
Principal Inventor	US Provisional Patent Side Chain Modification of Immunogenic Peptides for Use in Cancer Vaccines	2005
Principal Inventor	US Provisional Patent 60/442,777 Collapsible Large Volume Fluid Warmer for the Austere Trauma Environment	2003
Principal Inventor	US Patent 5,550,214 Isolated Antigenic Oncogene Peptide Fragments and Uses	1994

INVESTIGATIONAL NEW DRUG APPLICATIONS

1.	PI:	Folate Binding Protein (FBP) Attenuated Peptide J65 Vaccine (BB-IND (BB-IND 15305)	2013-
2.	PI:	HER-2/neu Peptide (GP2, NeoMPS) with Granulocyte-Macrophage Colony-Stimulating Factor and HER2/neu Peptide (AE37, NeoMPS) with Granulocyte-Macrophage Colony-Stimulating Factor (BB-IND 13740)	2008-
3.	PI:	Folate Binding Protein Peptide (E39, NeoMPS) with Granulocyte-Macrophage Colony-Stimulating Factor (Immunex) Adjuvant; Administered Interdermal (BB-IND 12391)	2006-
4.	PI:	HER-2/neu Peptide (GP2, Multiple Peptide Systems) with Granulocyte-Macrophage Colony-Stimulating Factor (Immunex) Adjuvant (BB-IND 11730)	2004-
5.	PI:	Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-Expressing Breast Cancer Patients to Prevent Recurrence (BB-IND 14919)	2011-2013
6.	PI:	HER-2/neu Peptide (776-790 [AE37], NeoMPS) with Granulocyte-Macrophage Colony-Stimulating Factor (Immunex) Adjuvant; Administered Intradermal (BB-IND 12229)	2005-2010
7.	PI:	HER-2/neu Peptide (369-377, Multiple Peptide Systems) with Granulocyte-Macrophage Colony-Stimulating Factor (Immunex) Adjuvant (BB-IND 9187)	2000-2007

GRANTS

Recipient	Norwell, Inc. industry collaboration	2010-2012
Recipient	Aphera, Inc. industry collaboration	2008-2013
Recipient	Antigen Express, Inc. industry collaboration	2008-2013
Recipient	Antigen Express, Inc. industry collaboration	2006-2008
Recipient	Antigen Express, Inc. industry collaboration	2004-2005
Recipient	US Military Cancer Institute	2004-2011
Recipient	Clinical Breast Care Project	2001-2006
Recipient	Center for Prostate Disease Research	2000-2008
Recipient	Astra Zeneca Award for Clinical Research	1999

Recipient	U.T. MD Anderson Cancer Center Clinical Trainee Research Grant	1998
Co-Author	NIH R01 CA60662-01 The immune response to human ovarian cancer	1993-1997
Recipient	NIH Training Grant CA09535	1991-1993

PROTOCOLS

1.	PI:	Phase I/IIa Trial of Folate Binding Protein (FBP) Peptides (E39 and J65) Vaccines in Ovarian and Endometrial Cancer Patients	2013-
2.	PI:	Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-Expressing Breast Cancer Patients to Prevent Recurrence	2013-
3.	PI:	Phase Ib Trial of the HER2/neu Peptide (GP2) + GM-CSF Vaccine to Prevent Recurrences in Ovarian Cancer Patients	2009-
4.	PI:	A Multi-Center Phase I Evaluation of the Doublet MCH Class I and II HER2/neu Peptide Vaccines (GP2 and AE37, respectively) in HLA-A2 ⁺ or HLA-A3 ⁺ Patients with Intermediate- to High-Risk Breast and/or Ovarian Cancer	2008-
5.	PI:	Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/ <i>neu</i> Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2 ⁺ <u>OR</u> the Modified HER2/ <i>neu</i> Peptide AE37 + GM-CSF Vaccine versus GM-CSF alone in HLA-A2 ⁻ Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence	2007-
6.	PI:	Phase Ib Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients	2006-
7.	PI:	A Prospective, Randomized Study Comparing Sentinel Lymph Node (SLN) Evaluation with Standard Pathological Evaluation for the Staging of Colon Carcinoma	2003-
8.	PI:	Sentinel Lymph Node (SLN) Evaluation in Colorectal Cancer (CRC)	2000-
9.	PI:	Ultrastaging of Early Colon Cancer	2009-2014
10.	PI:	Prospective Randomized Trial of Standard Wound Care Versus Standard Wound Care Plus Shock Wave Therapy for Traumatic Wounds of the Extremity	2008-2014
11.	PI:	Phase Ib Trial of Combination Immunotherapy with HER2/ <i>neu</i> Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients	2008-2014

12.	PI:	Phase I/II Trial of HER2/ <i>neu</i> Peptide (E75) Vaccine in Patients with Superficial Bladder Cancer	2006-2014
13.	PI:	Phase Ib Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Breast Cancer Patients	2005-2014
14.	PI:	Phase Ib Trial of HER2/ <i>neu</i> Peptide (GP2) Vaccine in Breast Cancer Patients	2004-2014
15.	PI:	Phase Ib Trial of a HER2/ <i>neu</i> Hybrid Peptide (AE37) Vaccine in Breast Cancer Patients	2005-2013
16.	PI:	Phase Ib Trial of HER2/ <i>neu</i> Peptide (E75) Vaccine in Node Negative Breast Cancer Patients	2003-2013
17.	PI:	Phase Ib Trial of HER2/ <i>neu</i> Peptide (E75) Vaccine in Breast Cancer Patients at High Risk for Recurrence after Surgical and Medical Therapies	2000-2013
18.	PI:	Pilot/Phase II Randomized Trial Comparing Best Available Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin + Best Available Systemic Therapy in Patients with Limited Peritoneal Dissemination of Colon Adenocarcinoma	2009-2012
19.	PI:	Phase Ib Trial of HER2/ <i>neu</i> Peptide (E75) Vaccine in Ovarian and Endometrial Cancer Patients	2006-2011
20.	PI:	Colorectal Cancer Care Quality Measurement System (CCQMS): A Veterans Affairs-Department of Defense (United States Military Cancer Institute) Cooperative Pilot Study	2009-2010
21.	PI:	Detection of Circulating Tumor Cells in Colorectal Carcinoma	2007-2010
22.	PI:	Serum Antibody and Cytokine Profiling Using Multiplex Technology for the Development of Screening Tests in Breast Cancer	2005-2010
23.	PI:	Cytotoxic T Lymphocyte Recognition of Epithelial Cancers	2000-2010
24.	PI:	Phase Ib Trial of HER2/ <i>neu</i> Peptide (E75) Vaccine in Patients at High Risk for Recurrence after Surgical Extirpation of Prostate Cancer	2000-2008
25.	PI:	Creation of a Database of Patients at High Risk for Breast Cancer	2000-2005
26.	PI:	Creation of a Database of Patients Evaluated and Treated for Breast Cancer	2000-2005

27.	PI:	A Randomized, Double Blind, Multi-center, BMS-284756 with or without Oral BMS-284756 Follow-up Versus Intravenous Piperacillin/Tazobactam with or without Oral Amoxicillin/Clavulanate Follow-up in the Treatment of Complicated Skin and Skin Structure Infections	2001-2002
28.	PI:	A Prospective Randomized Phase III Study Comparing Radiofrequency (RF) Ablation Versus Cryosurgical (CS) Ablation for the Treatment of Malignant Liver Tumors	2001-2003
29.	PI:	A Prospective, Randomized, Double Blind, Multi-center Trial Assessing the Safety and Efficacy of Sequential (Intravenous/Oral) BAY12-8093 (Moxifloxacin) 400 mg Every 24 Hours Compared to Intravenous Piperacillin/Tazobactam 3.375 g Every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800 mg Every 12 Hours for the Treatment of Patients with Complicated Intra-abdominal Infections	2001-2003

CANCER VACCINE DEVELOPMENT LAB FELLOW RESEARCH AWARDS

<i>Gayle B. Ryan</i>		2000-2001
▪	Washington Chapter, American College of Surgeons' Clinical Research Award	2001
▪	Joseph H. Baugh Clinical Research Award (Finalist)	2001
<i>Bryan A. Fisk</i>		2000-2001
▪	American College of Physicians' Associate Research Award	2001
▪	Bailey K. Ashford Basic Science Research Award (Finalist)	2001
<i>Michael M. Woll</i>		2001-2002
▪	Charles A. Hufnagel Basic Science Research Award (Finalist)	2002
▪	AACR-GlaxoSmithKline Outstanding Scholar Award	2002
▪	Bailey K. Ashford Basic Science Research Award (Finalist)	2004
<i>Jennifer M. Gurney</i>		2002-2003
▪	9 th National Symposium – Basic Aspects of Vaccines Scholarship Award	2003
▪	AACR-GlaxoSmithKline Outstanding Scholar Award	2003
<i>Matthew T. Hueman</i>		2003-2004
▪	10 th National Symposium – Basic Aspects of Vaccines Scholarship Award	2004
▪	AACR-GlaxoSmithKline Outstanding Scholar Award	2004
▪	Bailey K. Ashford Basic Science Research Award	2006
<i>Zia A. Dehqanzada</i>		2004-2005
▪	Washington Chapter, American College of Surgeons' Clinical Research Award	2005
▪	Joseph H. Baugh Clinical Research Award (Finalist)	2005
▪	Uniformed Services University of the Health Sciences Research Day President's Poster Selection	2005

▪ Bailey K. Ashford Laboratory Award (Semifinalist)	2007
<i>Steven Khoo</i>	2005-2006
▪ Charles A. Hufnagel Basic Science Research Award (Finalist)	2006
<i>Jarrold P. Holmes</i>	2006-2007
▪ American Society of Clinical Oncology Foundation Merit Award	2007
▪ Bailey K. Ashford Clinical Award (Semifinalist)	2007
▪ Bailey K. Ashford Poster Competition Winner	2007
▪ San Antonio Breast Cancer Symposium AstraZeneca Clinical Scholars Award	2007
▪ Military Health System Conference Award	2008
<i>Linda C. Benavides</i>	2007-2008
▪ Brooke Army Medical Center DCI Molecular Biology Course Infectious Disease Clinical Research Program	2007
▪ AACR-Bristol-Meyers-Squib Oncology Scholar-in-Training Award	2008
▪ Commander's Award, 1 st Place – Best research by graduating BAMC resident	2008
<i>Jeremy D. Gates</i>	2007-2008
▪ Brooke Army Medical Center DCI Molecular Biology Course Infectious Disease Clinical Research Program	2007
▪ Commander's Award, 2 nd Place - BAMC	2008
<i>Mark G. Carmichael</i>	2007-2008
▪ San Antonio Breast Cancer Symposium AstraZeneca Clinical Scholars Award	2007
▪ Military Health System Conference Award	2008
▪ AACR-AstraZeneca Scholar-in-Training Award	2008
<i>G. Travis Clifton</i>	2009-2010
▪ Brooke Army Medical Center Research Day – Commander's Award	2012
<i>Alan K. Sears</i>	2010-2011
▪ American Society of Clinical Oncology Foundation Merit Award	2011
<i>Diane F. Hale</i>	2011-2012
▪ AACR Scholar-in-Training Award (Susan G. Komen Foundation)	2011
▪ AACR Press Release Presentation	2012
▪ Brooke Army Medical Center Research Day – 3 rd Place, Resident Podium Presentation	2012
<i>Timothy J. Vreeland</i>	2011-2012
▪ AACR Scholar-in-Training Award 2012	2011
▪ Conquer Cancer Foundation of ASCO Merit Award	2012
▪ Brooke Army Medical Center Research Day – 1 st Place, Resident Podium Presentation	2012
▪ SAUSHEC Research Day Resident Podium Competition, 1 st place	2012
▪ Society of Air Force Clinical Surgeons General Surgery Surgeon General Award	2012
<i>Jaime Berry</i>	

- SAGES Military Symposium Award 2016

Erika Schneble

- AACR Scholar-in-Training Award 2014 2014
- SSO 2014 Best Clinical Research Poster Top 5 Finalist 2014
- Conquer Cancer Foundation of ASCO Merit Award 2014

Juila Greene

- Excellence in Research Award (Breast), American College of Surgeons Annual Clinical Congress 2015
- San Antonio Breast Cancer Symposium AstraZeneca Clinical Scholars Award 2015

SOCIETY MEMBERSHIPS

- Society for Immunotherapy of Cancer 2011-
- American Society of Clinical Oncology 2011-
- Ten Outstanding Young Americans Alumni Association 2001-
- American College of Surgeons, Fellow 1998-
- Society of Surgical Oncology, Active Member 1998-
- American Association for Cancer Research 1996-
- American Medical Association 1991-
- Alpha Omega Alpha 1988-
- Phi Beta Kappa 1988-
- Phi Kappa Phi 1983-

LICENSURE

- Texas License #K0989 1996-
- Massachusetts License #74840 (inactive) 1991-1996

SPECIALTY BOARDS

- General Surgery Certificate #42329 1997-2017